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A. Antarease II (Anil) 
10 2O 3 O 4 O 5 O 
An II DDDCIVVEYYI VTDSAFTKRF KSNSALTNYV TVMFTGVOET, L, DTLNLGIGV 
6O 7 O 8O 9 O 1 OO 
An II RLLGVTTFTE KTEPSFIKDN LIPGPPAAFD PDVLISAMSK YYCNHOTGLA 
11 O 12 O 13 O 1 4 O 15 O 
An II KDTDLIFLIT ARGMGDPRED GTVDINTAGI ANSAGVCKPC EKSGIATDES 
16O 17 O 18O 19 O 2OO 
An II DYNERVDTLA HES WHILLGSP HDGEGPNLVS LGSPGAANCP AKAGYIMGNR 
21 O 22 O 230 24 O 
An II NDKVNKYKFS NCTKKCVEYL LSKPTASCIF OOCSD 235 





NDKVNKYKFSNCTKKCVEYLLSKPTASCIFQQCSD SEQ ID NO: 2 
B. A reverse translation of ANIl: 
gatgatgattgcattgttggtggaat attatattgttgaccgatagog.cgtttaccaaacgc 
tittaaaag Caa Cag CGCGCtgaCCaactatgtgaCCdtgatgtttaccggCdtgcaggaa 
CtgCtggata CCCtgaaCCtgggcattgg Cdtgcgc.ctgctggg.cgtgaccacct ttacc 
gaaaaaacCQaaCC gag Cttt attaaagata acct gattic.cggg.ccc.gc.cgg.cgg.cgttt 
gat CCggatgttgCtgattag CGC gat gag Caaat attatt gCaaCCat Caga CC gcCCtg 
CCCaaagata CC gat Citgatttitt Ctgatta CCGC gCg Cgg Catggg.cg at CC gC gCCaa 
gatgg CaCCgtggat attaa CaCCCC ggg CattgCgala Cag CGCggg.cgtgttgcaaaccg 
tgCtttaaaag CCGCattgCgaCC gatgatag CQattataacgaacg.cgtggataccctg 
gC gCatgaaag CCtgCatctgctggg Cag CCC gCatgatggCdaagg.ccc.gaacCtggtg 
agcCtggg Cag CCC ggg CoCggCQaact gCCCgg.cgaaag.cgggctatat tatgggcaac 
Cg Caacgataaagtgaacaaatataaatttagcaactgcaccaaaaaatgcgtggaatat 
CtgCtgag Caaa CC gaCCgC gag Citg Catttitt Cag Cagt gCag Cat SEQ ID NO: 9 
C. A second reverse translation of ANIl: 
gay gay gaytgyathgtngtingartaytayathgtna Cingaywsng Cntitya Cnaarmgn 
ttyaar WSnaaywsng Cnytnacnaaytaygtnacingtnatgttyacing gngtncargar 
ytnytingaya Cnytnaayyting gnathgging timmgnytnytinggingtnacnacnttyacn 
garaaracng arccnwsnittyathaargayaayytnathccing gnccinccing cng cnitty 
gay CCngaygtnytnathWSng CnatgWSnaartaytaytgyaay CayCara Cng gnytn 
gCnaargaya Cngayytnathttyytnatha Cng Cnmging gnatgggingay CCnmgngar 
gayggnacingtingayathaaya Cng Cng gnathg CnaayWSng Cngging tint gyaar CCn 
tgytty alarWSng gnathgCna Cingay gay WSngaytayaay garngngtingaya Cnytn 
gCn Caygarw Sngtin Cayytnyting gnWSnCCn Cay gayggngar ggnCCnaayyting trh 
WSnytinggnWSnCCngging Cng Cnaaytgy congcnaarg Cinggintayathatgg gnaay 
mgnaaygayaargtnaayaartayaarttyWSnaaytoyacnaaraartgygtngartay 
ytnytnWsnaar CCnacing Cn WSntgyathttyCarCartgyWisngay SEQ ID NO: 10 
Fig.11 
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1. 
FAST ACTING SNARE-CLEAVING ENZYMES 
STATEMENT OF PRIORITY 
This application is a 35 U.S.C. S371 national phase appli 
cation of International Application Serial No. PCT/US2010/ 
045701, filed Aug. 17, 2010, which claims the benefit, under 
35 U.S.C. S 119 (e), of U.S. Provisional Application No. 
61/234,429, filed Aug. 17, 2009, the entire contents of which 
are incorporated by reference herein. 
STATEMENT REGARDING ELECTRONIC 
FILING OF A SEQUENCE LISTING 
A Sequence Listing in ASCII text format, submitted under 
37 C.F.R.S 1.821, entitled 5218-186ST25.txt, 23,437 bytes in 
size, generated on Jan. 20, 2015 and filed via EFS-Web, is 
provided in lieu of a paper copy. This Sequence Listing is 
hereby incorporated by reference into the specification for its 
disclosures. 
FIELD OF THE INVENTION 
The present invention provides metalloprotease enzymes 
isolated from scorpion venom that cleave SNARE complex 
proteins, their nucleic acid and amino acid sequences, and 
methods of use thereof in the treatment of various diseases, 
disorders and cosmetic conditions. 
BACKGROUND OF THE INVENTION 
Eukaryotic intracompartmental transport and secretory 
processes require fusion of vesicles with cellular membranes 
(1, 2, 3). A step leading to fusion of vesicles with cellular 
membranes is assembly of a tetrameric coiled-coil structure 
formed from sets of membrane proteins known as SNAREs 
(4) (soluble N-ethyl maleimide sensitive factor attachment 
protein receptors) (4). High-resolution structures are avail 
able for the final, post-fusion ternary SNARE complex that 
combines one vesicle protein (V-SNARE) with two target 
membrane proteins (t-SNARES). The SNAREs responsible 
for neuronal Secretion are among the best-studied examples 
of this family of proteins. They include the V-SNAREVAMP 
(vesicle-associated membrane protein) that is located on the 
secretory vesicle membrane and two t-SNAREs—syntaxin 
(SX) and SNAP25 (synaptosomal-associated protein 25) 
present on the target membrane (5. 6). 
SNAREs are responsible for selective transport between 
cellular compartments (7.8). Alterations or damage to pro 
teins or membranes that perform integral transport functions 
often produce disabling or irreversible consequences. Failure 
of the normal vesicular traffic (unless transient), which is the 
basis for intracellular transport and secretion, results in devel 
opment of disease (9, 10). As a consequence, toxins that 
attack this machinery have significant effects on normal cel 
lular processes. 
Proteolytic cleavage of SNARE family components is cur 
rently known to be associated only with large microbial pro 
teins from the genus Clostridium. These clostridial proteins 
require intracellular cleavage before they are released as 
smaller active proteolytic enzymes (23, 24, 25, 26). The 
present inventors have identified and isolated enzymes from 
scorpion venom that cleave also the SNARE complex pro 
teins. These enzymes are unique from the clostridial enzymes 
with respect to their mechanism of cleavage, specific cleav 













SUMMARY OF THE INVENTION 
The present invention provides, in one aspect, an isolated 
polypeptide comprising an amino acid sequence selected 
from the group consisting of (1) SEQID NO:1, (2) SEQID 
NO:2, (3) SEQID NO:3, (4) SEQID NO:4, (5) SEQID NO:5 
and SEQID NO:6, (6) SEQID NO:7 and SEQID NO:8, and 
a biologically active fragment thereof. 
In other aspects, the present invention provides an isolated 
nucleic acid encoding a polypeptide comprising an amino 
acid sequence selected from the group consisting of (1) SEQ 
ID NO:1, (2) SEQID NO:2, (3) SEQID NO:3, (4) SEQID 
NO:4, (5) SEQID NO:5 and SEQID NO:6 and (6) SEQID 
NO:7 and SEQID NO:8. 
In some aspects of the invention an isolated nucleic acid 
encoding a nucleotide sequence is provided, which is selected 
from the group consisting of: (a) the nucleotide sequence 
encoding a polypeptide comprising the amino acid sequence 
of (1) SEQID NO:1, (2) SEQID NO:2, (3) SEQID NO:3, (4) 
SEQID NO:4, (5) SEQID NO:5 and SEQ ID NO:6 or (6) 
SEQ ID NO:7 and SEQID NO:8; (b) a nucleotide sequence 
having at least 80% sequence identity to (a) above; and (c) a 
nucleotide sequence that differs from the nucleotide 
sequences of (a) or (b) above due to the degeneracy of the 
genetic code. 
Further aspects of this invention include an isolated nucleic 
acid encoding a nucleotide sequence selected from the group 
consisting of: (a) the nucleotide sequence of SEQID NO:9 
and SEQID NO:10; (b) a nucleotide sequence having at least 
80% sequence identity to (a) above; and (c) a nucleotide 
sequence that differs from the nucleotide sequences of (a) or 
(b) above due to the degeneracy of the genetic code. 
A further aspect of the present invention is a composition 
comprising an isolated polypeptide of the present invention in 
a pharmaceutically acceptable carrier. 
Another aspect of the invention is a composition compris 
ing an isolated nucleic acid of the invention in a pharmaceu 
tically acceptable carrier. 
In addition, the present invention provides methods of 
treating spasmodic muscles in a subject by administering to 
said Subject an effective amount of a composition of the 
present invention as described herein. 
In some embodiments, a method of treating and/or prevent 
ing a cosmetic condition in a Subject, comprising administer 
ing to the Subject an effective amount of a composition 
described herein, wherein the cosmetic condition is selected 
from the group consisting of frown wrinkles, forehead 
wrinkles, wrinkles around the eye (crow's feet), nose crease 
wrinkles, and combinations thereof. 
Further provided is a method of treating and/or preventing 
a disorder in a subject, comprising administering to the Sub 
ject an effective amount of a composition of the present 
invention as described herein, wherein the disorder is selected 
from the group consisting of Strabismus, blepharospasm, 
headache pain including pain due to a migraine headache, 
cervical dystonia, severe primary axillary hyperhidrosis, pro 
static symptoms, asthma, stroke symptoms, diabetes, 
obstructive pulmonary disease, achalasia, and combinations 
thereof. 
These and other aspects of the invention will be set forth in 
more detail in the description of the invention that follows. 
BRIEF DESCRIPTION OF THE FIGURES 
FIGS. 1A-D illustrate TSV (Tityus serrulatus venom) 
cleavage of synaptobrevins in pancreatic lobules in vitro. 
FIG. 1A shows dose-response curves for TSV. Fx v (Fraction 
US 9,149,666 B2 
3 
v), FX w. (Fraction ) effects on secretion of radiolabeled 
(newly-synthesized) proteins. FIG. 1B shows Western blots 
for phosphotyrosine (PY20), VAMP2 and VAMP3 illustrat 
ing TSV dose effect on VAMP and PY20 degradation. The 
TSV doses of 50 ug/ml and 5ug/ml are hyperstimulatory for 
secretion. The 1 lug/ml dose is optimal (see FIG. 1A). Control 
lobules are in Krebs Ringer Bicarbonate (KRB). FIG. 1C 
shows the time-course for incubations at two temperatures. 
TSV concentration is 50 lug/ml. FIG.1D shows Western blots 
for VAMP2 and VAMP8 in lobules incubated for 3 hours in 
optimal stimulatory doses for carbachol (CARE) (10 uM), 
caerulein (CAER) (1 nM) and hyperstimulatory Tx Y (secre 
tagogue toxin gamma) dose (100 nM) and TSV. For samples 
in FIGS. 1B, C and D. n=4 or 2 experiments with duplicate 
flasks. 
FIGS. 2A-F provide Immunogold VAMP2 electron micro 
graphs. Pancreatic lobules were incubated in vitro for 1 h at 
37° C. FIG. 2A shows the unstimulated control. Zymogen 
granules (ZG) are positively immunostained for VAMP2 
shown as 10 nm gold (Au) particles (arrows). FIG. 2B illus 
trates hyperstimulation with 100 ug/ml TSV. The absence of 
Au particles signifies the loss of VAMP2. FIG. 2C shows that 
optimal stimulation with 10 uM carbachol retains VAMP2. 
FIG. 2D shows that maximal stimulation with 1.0 ug/ml TSV 
indicates VAMP2 is conserved but fewer Au particles are 
present. FIG. 2E shows negative primary Ab using unstimu 
lated control. L-acinar lumen. FIG. 2F: Bar graph of statis 
tical analysis of Au distribution. The number of micrographs 
analyzed for each condition were: A: 23, B: 22, C: 10, D: 30, 
E: 12. Scale Bars: 0.5um. 
FIGS. 3A-D show cleavage of synaptobrevins by TSV and 
Fx v in Zymogen granules (ZG) and Zymogen granule mem 
branes (ZGM) in vitro. After in vitro incubation at 37°C., ZG 
or ZGM (25 g/lane) were analyzed by SDS-PAGE followed 
by Western blot. FIG.3A shows the effect of 50 g/ml TSV on 
VAMP2 in isolated pancreatic ZG: FIG. 3B shows the effect 
of 50 g/ml TSV on VAMP2 in isolated pancreatic ZGM. 
FIG. 3C shows the effect of 10 g/ml Fx v on VAMP8. FIG. 
3D shows the effects of 50 lug/ml TSV and 10 ug/ml Fx v on 
VAMP2 and tyrosine phosphorylation (PY20) in isolated ZG 
in vitro. Number of experiments: ZG, n=10. ZGM, n=4. 
FIGS. 4A-E show the characterization of TSV and FX v 
cleavage of recombinant synaptobrevins via transblots. FIG. 
4A: 10 MVAMP2 proteins incubated in vitro at 37°C. for 30 
min with 10 g/ml TSV or 50 g/ml Fx v or FX w. WT: Wild 
Type rat VAMP2 cytoplasmic portion 1-94. E41C: Mutant rat 
VAMP2 cytoplasmic portion 1-94. FIG. 4B: Inhibition of 10 
ug/ml FX v proteolytic activity by 60 min pre-incubation with 
10 mM EDTA, pH 7, in vitro at 37° C. 10 uMVAMP2 1-94 
proteins were then added for further 60 min incubation. FIG. 
4C: VAMP2 proteins incubated in vitro at 37° C. for 30 min 
with Fx v. WT: Wild Type 10 uM rat VAMP2 cytoplasmic 
portion 1-96, K85A-R86S-K87A: Mutant 10 uM rat VAMP2 
cytoplasmic portion 1-96 with altered cleavage site. FIG. 4D: 
Time-course for WT 10 MVAMP2 cleavage by 10 g/ml FX 
vat 37° C. FIG. 4E: 10 MVAMP2 cleavage during incuba 
tion in vitro at 37° C. for 30 min with 50 g/ml Centruroides 
sculpturatus venom (CSV). The number of experiments 
under various conditions for each SNARE protein was as 
follows: WTV2 1-94, n=20; V2 E41C, n=11; WTV2 1-96, 
n=9: V2 K85A-R86S-K87A, n=3. 
FIGS.5A-B show the isolation of cleaved VAMP2 peptides 
using Cs reverse phase chromatographic separation of WT 
10 uMVAMP2 (1-94) peptides after invitro incubation at 37° 
C. for 30 min. FIG. 5A: 10 g/ml Fx v cleaved VAMP2 















FIG. 6 provides a molecular model of VAMP2 and descrip 
tion of cleavage sites by clostridial toxins and FX v. Top: 
VAMP2 and VAMP8 (rat) FASTA homology alignment with 
transmembrane segments (95-113). Center: VAMP2 amino 
acid sequence coordinated with molecular model reflecting 
sequence features. Bottom: Fx v cleavage (85, 86, 87) at 
broken ribbon, BoNT/F (at K52), /D (at R56), /G (at A81) and 
/B; and TeNT cleavages (F77) and arrows, and SNARE 
motifs, X1 (A37-R47) and X2 (S61-Q71). Model and FASTA 
homology generated by Insight|I (Accelrys). BoNT (botuli 
num toxin; /F, /D, 70 and /B represent the botulinum toxin 
serotypes); TeNT (tetanus toxin). 
FIG. 7 shows in transblots that TSV and FX v cleave other 
recombinant SNARE proteins. WT90 uMhuman endobrevin 
(VAMPS) cytoplasmic portion 1-74 or WT 20 uM rat 
SNAP25 full length 1-206 was incubated with either 10 ug/ml 
TSV or 10 pg/ml Fx v in vitro at 37° C. for 30 min. Number 
of experiments: VAMP8, n=3; SNAP25, n=7. 
FIG. 8 shows in transblots Fx v degradation of assembled 
SNARE complex. SNARE complex (CPX) was incubated 
with 10 g/ml Fx v in vitro at 37°C. for 60 min. After mixing 
with Laemmli buffer, one sample was loaded onto a gel as 
intact complex (not boiled) and another sample was disas 
sembled by boiling for 5 min prior to loading (boiled). The 
image is representative of 14 blots from 3 experiments using 
3 sequentially purified SNARE complexes. 
FIG. 9A-B show the chromatographic separation of FX v 
and isolation of Antarease I. FIG.9Ashows the size exclusion 
separation of Tityus serrulatus whole venom with Sephadex 
G-50. FIG. 9B shows the anion exchange chromatographic 
isolation of Fx v metalloproteases. Pools I, II, III, IV, and Pool 
III fractions 1-9 were incubated with WT20 MVAMP21-96 
in vitro at 37° C. for 30 minutes to detect protease activity. 
Insets are transblots of incubation samples. 
FIG. 10 shows an alignment of the amino acid sequences 
for two proteins isolated from Tityus serrulatus (TSV) desig 
nated AnI (Antarease I) (SEQID NO: 1) and Anil (Antarease 
II) (SEQID NO:2) and two proteins isolated from Centruroi 
des sculpturatus (CSV) designated AZI (AZantarease I) (SEQ 
ID NO:3) and AZII (AZantarease II) (SEQ ID NO:4). Com 
pare Anland AnII: Same=122; Similar:=36: An IX=14; Com 
pare Ann and AZI: Same=113; Similar:=24; Ann x=15; AZI 
X=36. 
FIGS. 11 A-C show (FIG. 11A) the amino acid sequence of 
Antarease II (SEQ ID NO:2) and two reverse translations 
(FIGS. 11B and C) (SEQID NO:9 and SEQID NO:10) of the 
amino acid sequence of SEQID NO:2. FIG. 11B shows the 
reverse translation of An II to a 708 base sequence of most 
likely codons (SEQID NO:9) and FIG.11C shows the reverse 
translation of An II to a 708 base sequence of consensus 
codons (SEQID NO:10). 
DETAILED DESCRIPTION 
Particular aspects of this invention are explained in greater 
detail below. This description is not intended to be a detailed 
catalog of all the different ways in which the invention may be 
implemented, or all the features that may be added to the 
instant invention. For example, features illustrated with 
respect to one embodiment may be incorporated into other 
embodiments, and features illustrated with respect to a par 
ticular embodiment may be deleted from that embodiment. In 
addition, numerous variations and additions to the various 
embodiments suggested herein will be apparent to those 
skilled in the art in light of the instant disclosure that do not 
depart from the instant invention. Hence, the following speci 
fication is intended to illustrate some particular embodiments 
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of the invention, and not to exhaustively specify all permuta 
tions, combinations and variations thereof. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
belongs. The terminology used in the description of the inven 
tion herein is for the purpose of describing particular embodi 
ments only and is not intended to be limiting of the invention. 
All publications, patent applications, patents, and other ref 
erences mentioned herein are incorporated by reference in 
their entirety 
As used herein, “a,” “an or “the can mean one or more 
than one. For example, a cell can mean a single cell or a 
multiplicity of cells. 
As used herein, “and/or refers to and encompasses any 
and all possible combinations of one or more of the associated 
listed items, as well as the lack of combinations when inter 
preted in the alternative (or). 
Further, the term “about, as used herein when referring to 
a measurable value Such as an amount of a compound or 
agent, dose, time, temperature, and the like, is meant to 
encompass variations of +20%, it 10%, 5%, +1%, +0.5%, or 
even 0.1% of the specified amount. 
As used herein, the terms “protein’ and “polypeptide' are 
used interchangeably and encompass peptides, unless indi 
cated otherwise. In the protein sequences presented herein, 
the one-letter code X, X, Xaa or Xaa refers to an amino acid 
that is optionally present or absent and can be any naturally 
occurring amino acid. 
The terms “polypeptide.” “protein, and "peptide' refer to 
a chain of covalently linked amino acids. In general, the term 
"peptide' can refer to shorter chains of amino acids (e.g., 2-50 
amino acids); however, all three terms overlap with respect to 
the length of the amino acid chain. Polypeptides, proteins, 
and peptides may comprise naturally occurring amino acids, 
non-naturally occurring amino acids, or a combination of 
both. The polypeptides, proteins, and peptides may be iso 
lated from Sources (e.g., cells or tissues) in which they natu 
rally occur, produced recombinantly in cells in vivo or in vitro 
or in a test tube in vitro, or synthesized chemically. Such 
techniques are known to those skilled in the art. See, e.g., 
Sambrook et al., Molecular Cloning: A Laboratory Manual 
2nd Ed. (Cold Spring Harbor, N.Y., 1989); Ausubel et al. 
Current Protocols in Molecular Biology (Green Publishing 
Associates, Inc. and John Wiley & Sons, Inc., New York). 
The term “fragment, as applied to a polypeptide, will be 
understood to mean an amino acid sequence of reduced 
length relative to a reference polypeptide or amino acid 
sequence and comprising, consisting essentially of and/or 
consisting of an amino acid sequence of contiguous amino 
acids identical to the reference polypeptide or amino acid 
sequence. Such a polypeptide fragment according to the 
invention may be, where appropriate, included in a larger 
polypeptide of which it is a constituent. In some embodi 
ments, such fragments can comprise, consist essentially of 
and/or consist of peptides having a length of at least about 4. 
6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, 
or more consecutive amino acids of a polypeptide or amino 
acid sequence according to the invention. 
A fragment of a polypeptide or protein of this invention can 
be produced by methods well known and routine in the art. 
Fragments of this invention can be produced, for example, by 
enzymatic or other cleavage of naturally occurring peptides 
or polypeptides or by synthetic protocols that are well known. 
Such fragments can be tested for one or more of the biological 
activities of this invention (e.g., cleavage of SNARE complex 













are routine methods for testing activities of polypeptides, 
and/or according to any art-known and routine methods for 
identifying Such activities. The production and testing to 
identify biologically active fragments of the polypeptides 
described herein would be well within the scope of one of 
ordinary skill in the art and would be routine. Thus, the 
present invention further provides biologically active frag 
ments of the polypeptides of the present invention and the 
polynucleotides encoding Such biologically active polypep 
tide fragments. 
As used herein, “nucleic acid.” “nucleotide sequence' and 
"polynucleotide' refer to a chain of nucleotides without 
regard to length of the chain and encompass both RNA and 
DNA, including cDNA, genomic DNA, mRNA, synthetic 
(e.g., chemically synthesized) DNA and chimeras of RNA 
and DNA e.g., DNA-RNA hybrid sequences (including both 
naturally occurring and non-naturally occurring nucle 
otides), but are typically either single or double stranded 
DNA or RNA sequences. Where single-stranded, the nucleic 
acid can be a sense strand or an antisense Strand. The nucleic 
acid can be synthesized using oligonucleotide analogs or 
derivatives (e.g., inosine or phosphorothioate nucleotides). 
Such oligonucleotides can be used, for example, to prepare 
nucleic acids that have altered base-pairing abilities or 
increased resistance to nucleases. The present invention fur 
ther provides a nucleic acid that is the complement (which can 
be either a full complement or a partial complement) of a 
nucleic acid or nucleotide sequence of this invention. 
The nomenclature used in the nucleotide sequences pre 
sented herein follows that of the International Union of Bio 
chemistry and Molecular Biology (IUBMB) (www. 
chem.dmul.ac.uldiubmb?). Thus, G, A, T, C refers to guanine, 
adenine, thymine, cytosine, respectively; R refers to purine 
(adenine or guanine); Y refers to pyrimidine (thymine or 
cytosine); W refers to adenine or thymine; S refers to guanine 
or cytosine; M refers to adenine or cytosine: K refers to 
guanine or thymine; H refers to adenine or thymine or 
cytosine; B refers to guanine or cytosine or thymine; V refers 
to guanine or adenine or cytosine; D refers to guanine or 
adenine orthymine; N refers to guanine oradenine or thymine 
or cytosine. 
The terms “complementary' or “complementarity, as 
used herein, refer to the natural binding of polynucleotides 
under permissive salt and temperature conditions by base 
pairing. For example, the sequence “A-G-T binds to the 
complementary sequence "T-C-A’ Complementarity 
between two single-stranded molecules may be “partial.” in 
which only some of the nucleotides bind, or it may be com 
plete when total complementarity exists between the single 
stranded molecules. The degree of complementarity between 
nucleic acid strands has significant effects on the efficiency 
and strength of hybridization between nucleic acid strands. 
The term “nucleic acid fragment will be understood to 
mean a nucleotide sequence of reduced length relative to a 
reference nucleic acid or nucleotide sequence and compris 
ing, consisting essentially of and/or consisting of a nucleotide 
sequence of contiguous nucleotides identical or almost iden 
tical (e.g., 80%, 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 98%, 99% 
identical) to the reference nucleic acid or nucleotide 
sequence. Such a nucleic acid fragment according to the 
invention may be, where appropriate, included in a larger 
polynucleotide of which it is a constituent. In some embodi 
ments, such fragments can comprise, consist essentially of 
and/or consist of oligonucleotides having a length of at least 
about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 
22, 23, 24, 25, 50, 75, 100, 150, 200, 250, 300,350, 400, 450, 
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500, 750, or 1000 consecutive nucleotides of a nucleic acid or 
nucleotide sequence according to the invention. 
An "isolated nucleic acid is a nucleotide sequence (e.g., 
DNA or RNA) that is not immediately contiguous with nucle 
otide sequences with which it is immediately contiguous (one 
on the 5' end and one on the 3' end) in the naturally occurring 
genome of the organism from which it is derived. Thus, in one 
embodiment, an isolated nucleic acid includes some or all of 
the 5' non-coding (e.g., promoter) sequences that are imme 
diately contiguous to a coding sequence. The term therefore 
includes, for example, a recombinant DNA that is incorpo 
rated into a vector, into an autonomously replicating plasmid 
or virus, or into the genomic DNA of a prokaryote or eukary 
ote, or which exists as a separate molecule (e.g., a cDNA or a 
genomic DNA fragment produced by PCR or restriction 
endonuclease treatment), independent of other sequences. It 
also includes a recombinant DNA that is part of a hybrid 
nucleic acid encoding an additional polypeptide or peptide 
Sequence. 
The term "isolated can further refer to a nucleic acid, 
nucleotide sequence, polypeptide, peptide or fragment that is 
substantially free of cellular material, viral material, and/or 
culture medium (e.g., when produced by recombinant DNA 
techniques), or chemical precursors or other chemicals (e.g., 
when chemically synthesized). Moreover, an "isolated frag 
ment' is a fragment of a nucleic acid, nucleotide sequence or 
polypeptide that is not naturally occurring as a fragment and 
would not be found as such in the natural state. “Isolated 
does not mean that the preparation is technically pure (homo 
geneous), but it is Sufficiently pure to provide the polypeptide 
or nucleic acid in a form in which it can be used for the 
intended purpose. 
In representative embodiments of the invention an “iso 
lated nucleic acid, nucleotide sequence, and/or polypeptide 
is at least about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 
60%, 70%, 75%,80%, 85%, 90%, 95%,97%.98%,99% pure 
(w/w) or more. In other embodiments, an "isolated nucleic 
acid, nucleotide sequence, and/or polypeptide indicates that 
at least about a 5-fold, 10-fold, 25-fold, 100-fold, 1000-fold, 
10,000-fold, 100,000-fold or more enrichment of the nucleic 
acid (W/w) is achieved as compared with the starting material. 
The term “operably linked’ refers to the association of 
nucleic acid sequences on a single nucleic acid fragment so 
that the function of one is affected by the other. For example, 
a promoter is operably linked with a coding sequence when it 
is capable of affecting the expression of that coding sequence 
(i.e., the coding sequence is under the transcriptional control 
of the promoter). Coding sequences can be operably linked to 
regulatory sequences in sense and/or antisense orientation. 
Thus, a coding sequence of the present invention may be 
operably linked to a regulatory sequence, thereby allowing its 
expression in a cell and/or Subject. 
Different nucleic acids or proteins having homology are 
referred to herein as “homologues.” The term homologue 
includes homologous sequences from the same and other 
species and orthologous sequences from the same and other 
species. “Homology” refers to the level of similarity between 
two or more nucleic acid and/or amino acid sequences in 
terms of percent of positional identity (i.e., sequence similar 
ity or identity). Homology also refers to the concept of similar 
functional properties among different nucleic acids or pro 
teins. 
As is well known in the art, nucleic acid sequences can have 
changes in one or more nucleotide bases that results in Sub 
stitution of one or more amino acids, but which do not affect 
the functional properties of the polypeptide encoded by the 













tion encompasses more than the specific exemplary nucle 
otide or amino acid sequences and includes functional 
equivalents thereof. 
For example, alterations in a gene which result in the pro 
duction of a chemically equivalent amino acid at a given site, 
but do not affect the functional properties of the encoded 
protein, are well known in the art. Thus, a codon for the amino 
acid alanine, a hydrophobic amino acid, may be substituted 
by a codon encoding another less hydrophobic residue. Such 
as glycine, or a more hydrophobic residue. Such as valine, 
leucine, or isoleucine. Similarly, changes which result in Sub 
stitution of one negatively charged residue for another, Such 
as aspartic acid for glutamic acid, or one positively charged 
residue for another, such as lysine for arginine, can also be 
expected to produce a functionally equivalent product. Each 
of the proposed modifications is well within the routine skill 
in the art, as is determination of retention of biological activ 
ity of the encoded products. 
Thus, the invention further provides homologues, as well 
as methods of obtaining homologues, of the polypeptides 
and/or fragments of this invention from other organisms 
included in this invention. As used herein, an amino acid 
sequence or protein is defined as a homologue of a polypep 
tide or fragment of the present invention if it shares significant 
homology or identity to a polypeptide, peptide and/or frag 
ment of the present invention. Significant homology or iden 
tity means at least 60%. 65%, 70%, 75%, 80%, 81%, 82%, 
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 
93%, 94%, 96%, 97%, 98%, 99% and/or 100% homology or 
identity with another amino acid sequence. Specifically, by 
using the nucleic acids that encode the proteins, peptides and 
fragments of this invention, as a probe or primer, and tech 
niques such as PCR amplification and colony/plaque hybrid 
ization, one skilled in the art can identify homologues of the 
polypeptides, peptides and/or fragments of this invention in 
other organisms on the basis of information available in the 
art. 
The term “percent identity,” as known in the art, describes 
a relationship between two or more polypeptide sequences or 
two or more polynucleotide sequences, as determined by 
comparing the sequences. In the art, “identity also means the 
degree of sequence relatedness between polypeptide or poly 
nucleotide sequences as determined by the match between 
strings of such sequences. “Identity” and “similarity' can be 
readily calculated by known methods including, but not lim 
ited to, those described in: Computational Molecular Biology 
(Lesk, A.M., ed.) Oxford University Press, New York (1988); 
Biocomputing: Informatics and Genome Projects (Smith, D. 
W., ed.) Academic Press, New York (1993); Computer Analy 
sis of Sequence Data, Part I (Griffin, A.M., and Griffin, H.G., 
eds.) Humana Press, New Jersey (1994); Sequence Analysis 
in Molecular Biology (von Heinje, G., ed.) Academic Press 
(1987); and Sequence Analysis Primer (Gribskov, M. and 
Devereux, J., eds.) Stockton Press, New York (1991). 
Accordingly, the present invention further provides nucle 
otide sequences having significant sequence similarity or 
identity to the nucleotide sequences of the present invention. 
Significant sequence similarity or identity means at least 
70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 
88%, 89%, 90%, 91%, 92%, 93%, 94%, 96%, 97%, 98%, 
99% and/or 100% similarity or identity with another nucle 
otide sequence. 
Exemplary methods to determine identity are designed to 
give the best match between the sequences tested. Methods to 
determine identity and similarity are codified in publicly 
available computer programs. Sequence alignments and per 
cent identity calculations can be performed using the Mega 
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lign program of the LASERGENE bioinformatics computing 
suite (DNASTAR Inc., Madison, Wis.). Multiple alignment 
of the sequences may be performed using the Clustal method 
of alignment (Higgins and Sharp (1989) CABIOS. 5:151 
153) with the default parameters (GAPPENALTY=10, GAP 
LENGTH PENALTY=10). Exemplary default parameters 
for pairwise alignments using the Clustal method can be 
selected: KTUPLE 1 GAPPENALTY=3, WINDOW=5 and 
DIAGONALS SAVED=5. 
The term "sequence analysis Software” refers to any com 
puter algorithm or software program that is useful for the 
analysis of nucleotide and/or amino acid sequences. 
Sequence analysis Software is commercially available or can 
be independently developed. Typical sequence analysis soft 
ware will include but is not limited to the GCG suite of 
programs (Wisconsin Package Version 9.0, Genetics Com 
puter Group (GCG), Madison, Wis.), BLASTP. BLASTN, 
BLASTX (Altschul et al., J. Mol. Biol. 215:03-410 (1990), 
and DNASTAR (DNASTAR, Inc. 1228 S. Park St. Madison, 
Wis. 53715 USA). Within the context of this application, it 
will be understood that where sequence analysis software is 
used for analysis, the results of the analysis will be based on 
the “default values” of the program referenced, unless other 
wise specified. As used herein “default values' will mean any 
set of values or parameters, which originally load with the 
software when first initialized. 
A percentage amino acid sequence identity value is deter 
mined by the number of matching identical residues divided 
by the total number of residues of the “longer” sequence in the 
aligned region. The "longer” sequence is the one having the 
most actual residues in the aligned region (gaps introduced by 
WU-Blast-2 to maximize the alignment score are ignored). 
The alignment can include the introduction of gaps in the 
sequences to be aligned. In addition, for sequences which 
contain either more or fewer amino acids than the polypep 
tides specifically disclosed herein, it is understood that in one 
embodiment, the percentage of sequence identity will be 
determined based on the number of identical amino acids in 
relation to the total number of amino acids. Thus, for 
example, in one embodiment, sequence identity of sequences 
shorter than a sequence specifically disclosed herein, will be 
determined using the number of amino acids in the shorter 
sequence. In percent identity calculations relative weight is 
not assigned to various manifestations of sequence variation, 
Such as insertions, deletions, Substitutions, etc. 
In other embodiments, only identities are scored positively 
(+1) and all forms of sequence variation including gaps are 
assigned a value of “0” which obviates the need for a 
weighted Scale or parameters as described below for sequence 
similarity calculations. Percent sequence identity can be cal 
culated, for example, by dividing the number of matching 
identical residues by the total number of residues of the 
“shorter” sequence in the aligned region and multiplying by 
100. The “longer sequence is the one having the most actual 
residues in the aligned region. 
The nucleic acid fragments of the instant invention may be 
used to isolate cDNAS and genes encoding homologous pro 
teins from the same or different organisms. Isolation of 
homologous genes using sequence-dependent protocols is 
well known in the art. Examples of sequence-dependent pro 
tocols include, but are not limited to, methods of nucleic acid 
hybridization, and methods of DNA and RNA amplification 
as exemplified by various uses of nucleic acid amplification 
technologies (e.g., polymerase chain reaction, ligase chain I 
reaction). 
For example, genes encoding other SNARE cleaving pro 













directly by using all or a Substantial portion of the nucleic acid 
fragments of the present invention as DNA hybridization 
probes to screen libraries from any desired organism employ 
ing methodology well known to those skilled in the art. Spe 
cific oligonucleotide probes based upon the instant nucleic 
acid sequences can be designed and synthesized by methods 
known in the art (See, e.g., Sambrook et al., Molecular Clon 
ing: A Laboratory Manual 2nd Ed. (Cold Spring Harbor, N.Y., 
1989); Ausubeletal. Current Protocols in Molecular Biology 
(Green Publishing Associates, Inc. and John Wiley & Sons, 
Inc., New York). Moreover, the entire sequence(s) can be used 
directly to synthesize DNA probes by methods known to the 
skilled artisan Such as random primer DNA labeling, nick 
translation, end-labeling techniques, or RNA probes using 
available in vitro transcription systems. In addition, specific 
primers can be designed and used to amplify apart orall of the 
instant sequences. The resulting amplification products can 
be labeled directly during amplification reactions or labeled 
after amplification reactions, and used as probes to isolate full 
length cDNA or genomic fragments under conditions of 
appropriate stringency. 
In addition, two short segments of the instant nucleic acid 
fragments may be used in polymerase chain reaction proto 
cols to amplify longer nucleic acid fragments encoding 
homologous genes from DNA or RNA. The polymerase chain 
reaction may also be performed on a library of cloned nucleic 
acid fragments wherein the sequence of one primer is derived 
from the instant nucleic acid fragments, and the sequence of 
the other primer takes advantage of the presence of the poly 
adenylic acid tracts to the 3' end of the mRNA precursor 
encoding arthropod genes. Alternatively, the second primer 
sequence may be based upon sequences derived from the 
cloning vector. For example, the skilled artisan can follow the 
RACE protocol (Frohman et al. (1988) Proc. Natl. Acad. Sci. 
USA 85:8998-9002) to generate cDNAs by using PCR to 
amplify copies of the region between a single point in the 
transcript and the 3' or 5' end. Primers oriented in the 3' and 5' 
directions can be designed from the instant sequences. Using 
commercially available 3' RACE or 5' RACE systems (BRL), 
specific 3' or 5' clNA fragments can be isolated (Ohara et al. 
(1989) Proc. Natl. Acad. Sci. USA 86:5673-5677; Loh et al. 
(1989) Science 243:217-220). Products generated by the 3' 
and 5 RACE procedures can be combined to generate full 
length cDNAs (Frohman and Martin (1989) Techniques 
1:165). 
A “therapeutic polypeptide' as used herein refers to a 
polypeptide that can alleviate or reduce symptoms that result 
from an absence or defect in a protein in a cell or Subject. 
Alternatively, a “therapeutic polypeptide' is a polypeptide 
that otherwise confers a benefit to a Subject, e.g., confers 
anti-spasmodic effects or an improvement in Strabismus. 
The term “therapeutically effective amount” or “effective 
amount, as used herein, refers to that amount of a composi 
tion of this invention that imparts a modulating effect, which, 
for example, can be a beneficial effect, to a subject afflicted 
with a disorder, disease or cosmetic condition, including 
improvement in the disease, disorder or cosmetic condition of 
the Subject (e.g., in one or more symptoms), delay or reduc 
tion in the progression of the disease, disorder or condition, 
prevention or delay of the onset of the disease, disorder or 
condition, and/or change in clinical parameters, disease or 
disorder, etc., as would be well known in the art. The effective 
amount will vary with the age, general condition of the Sub 
ject, the severity of the disease, disorder or condition being 
treated, the particular agent administered, the duration of the 
treatment, the nature of any concurrent treatment, the phar 
maceutically acceptable carrier used, and like factors within 
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the knowledge and expertise of those skilled in the art. As 
appropriate, an “effective amount in any individual case can 
be determined by one of ordinary skill in the art by reference 
to the pertinent texts and literature and/or by using routine 
experimentation. (See, for example, Remington, The Science 
and Practice of Pharmacy (20th ed. 2000)). For example, a 
therapeutically effective amount or effective amount can refer 
to the amount of a composition, compound, or agent that 
improves a disease, disorder or condition in a subject by, for 
example, at least 5%, at least 10%, at least 15%, at least 20%, 
at least 25%, at least 30%, at least 35%, at least 40%, at least 
45%, at least 50%, at least 55%, at least 60%, at least 65%, at 
least 70%, at least 75%, at least 80%, at least 85%, at least 
90%, at least 95%, or at least 100%. 
By the terms “treat,” “treating or “treatment of (or gram 
matically equivalent terms) it is meant that the severity of the 
Subjects disease, disorder or cosmetic condition is reduced or 
at least partially improved or ameliorated and/or that some 
alleviation, mitigation or decrease in at least one clinical 
symptom is achieved and/orthere is a delay in the progression 
of the disease, disorder or condition and/or prevention or 
delay of the onset of a disease, disorder, cosmetic condition, 
etc., as would be well known in the art.” Thus, unless the 
context indicates otherwise, the terms “treat,” “treating or 
“treatment of (or grammatically equivalent terms) refer to 
both prophylactic and therapeutic regimens. 
As used herein, the terms “prevent,” “prevents.” or “pre 
vention' (and grammatical equivalents thereof) are not meant 
to imply complete abolition of a disease, disorder or cosmetic 
condition and encompass any type of prophylactic action that 
reduces the incidence of the disease, disorder or condition, 
delays the onset and/or progression of the disease, disorder or 
condition, and/or reduces the symptoms associated with the 
disease, disorder or condition. 
Regulated secretion requires coordinated vesicular traf 
ficking for all processes including biosynthesis, transport, 
storage, and discharge (11, 12, 13). Signaling in exocrine 
secretion produces characteristic phosphorylation patterns of 
intracellular proteins that represent control mechanisms, but 
the connections between receptor activation and secretory 
discharge remain incompletely understood. 
Pancreatic exocrine secretory discharge is normally medi 
ated by neurological (cholinergic) and hormonal (peptider 
gic) controls that operate in parallel (14, 15). Earlier work by 
the present inventors showed that Scorpion Venom also ini 
tiates pancreatic secretion in vitro (16, 17). Clinical studies 
report that Scorpion venoms induce significant pathology 
including acute pancreatitis in humans following envenoma 
tion (18, 19). Experimental evaluation of cellular effects of 
Scorpion Venom and its bioactive components reveals signal 
ing that differs from patterns produced by the natural cholin 
ergic and peptidergic secretagogues (unpublished). Tissues 
treated with these venom preparations produce linear dose 
response curves in comparison with cholinergic and peptider 
gic exocrine pancreatic secretagogues; however, discharge is 
diminished at levels in excess of optimum secretory doses as 
we have published (16, 17, 20). 
Initial evidence of unique Scorpion Venom mediated activ 
ity on secretory mechanisms stemmed from the assessment of 
tyrosine phosphorylation of cellular proteins. These data pro 
vided the first information that cleavage changes to secretory 
SNARE proteins could disrupt cellular transport and secre 
tion functions (21, 22). 
The present invention is based on the unexpected discovery 
of metalloproteases isolated from Scorpion venom that can 
cleave SNARE complex proteins. Studies with recombinant 













seven residues from the membrane attachment segment, in 
the loop between the coiled-coil snare bundle binding region 
and the transmembrane segment adjacent to its carboxyl ter 
minus. VAMP8 is cleaved at a homologous site. The activity 
of the protease is dependent on divalent ions, which is in 
agreement with the zinc-binding motif present in the 
sequence. Previously, proteolytic cleavage of SNARE family 
components was known to be associated only with large 
microbial proteins from the genus Clostridium that require 
intracellular cleavage before release of smaller active pro 
teolytic enzymes (23, 24, 25, 26). 
Accordingly, the present invention provides, in one aspect, 
an isolated polypeptide comprising an amino acid sequence 
selected from the group consisting of (1) SEQID NO:1, (2) 
SEQID NO:2, (3) SEQID NO:3, (4) SEQID NO:4, (5) SEQ 
ID NO:5 and SEQ ID NO:6, (6) SEQID NO:7 and SEQID 
NO:8, and biologically active fragments thereof. 
Thus, some particular aspects of the present invention pro 
vide an isolated polypeptide comprising an amino acid 
sequence of SEQ ID NO:2. In other aspects, the present 
invention provides an isolated polypeptide comprising an 
amino acid sequence of SEQ ID NO:5 and an amino acid 
sequence of SEQID NO:6. In still other embodiments, the 
present invention provides a polypeptide comprising an 
amino acid sequence of SEQ ID NO:7 and an amino acid 
sequence of SEQID NO:8. Further aspects of the invention 
provide an isolated polypeptide comprising an biologically 
active fragment of an amino acid sequence selected from the 
group consisting of (1) SEQID NO:1, (2) SEQID NO:2, (3) 
SEQID NO:3, (4) SEQID NO:4, (5) SEQID NO:5 and SEQ 
ID NO:6, (6) SEQID NO:7 and SEQID NO:8. 
The isolated polypeptides of the present invention are pro 
teases, more specifically, they are metalloproteases and are 
designated Antarease I (ANI) (SEQID NO:1, SEQID NO:5 
and SEQ ID NO:6), Antarease II (ANTI) (SEQ ID NO:2), 
AZantarase I (AZI) (SEQID NO:3, SEQID NO:7 and SEQ 
ID NO:8), and Azantarease II (AZII) (SEQID NO:4). Antar 
ease I and II are isolated from venom of the South American 
scorpion Tityus serrulatus (TSV), while AZantarease I and II 
are isolated from the venom of a North American scorpion 
species, Centruroides sculpturatus (CSV). These enzymes 
are shown herein to have SNARE cleaving activity. This was 
a Surprising finding because previously the only known 
enzymes to cleave SNARE complex proteins were the 
clostridial neurotoxins (e.g., Clostridium botulinum toxin, 
Clostridium tetani toxin). 
The proteases of the present invention differ significantly 
from the clostridal proteases in both their structure (amino 
acid sequence) and their cleavage sites within the SNARE 
complex. In fact, it appears that the proteases of the present 
invention do not share significant homology with any amino 
acid sequence found in the current sequence databases. 
The present invention further provides an isolated nucleic 
acid encoding a polypeptide comprising an amino acid 
sequence selected from the group consisting of (1) SEQ ID 
NO:1, (2) SEQ ID NO:2, (3) SEQ ID NO:3, (4) SEQ ID 
NO:4, (5) SEQID NO:5 and SEQ. ID NO:6, and (6) SEQID 
NO:7 and SEQID NO:8. 
Other aspects of the invention provide an isolated nucleic 
acid encoding a nucleotide sequence selected from the group 
consisting of: (a) the nucleotide sequence encoding a 
polypeptide comprising the amino acid sequence of (1) SEQ 
ID NO:1, (2) SEQID NO:2, (3) SEQID NO:3, (4) SEQID 
NO:4, (5) SEQID NO:5 and SEQ ID NO:6, or (6) SEQ ID 
NO:7 and SEQID NO:8; (b) a nucleotide sequence having at 
least 85% sequence identity to (a) above; and (c) a nucleotide 
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sequence that differs from the nucleotide sequences of (a) or 
(b) above due to the degeneracy of the genetic code. 
Still other aspects of the invention provide an isolated 
nucleic acid encoding a nucleotide sequence selected from 
the group consisting of: (a) the nucleotide sequence encoding 
a polypeptide comprising the amino acid sequence of (1) SEQ 
ID NO:1, (2) SEQID NO:2, (3) SEQ ID NO:3, (4) SEQID 
NO:4, (5) SEQID NO:5 and SEQ ID NO:6, or (6) SEQ ID 
NO:7 and SEQID NO:8; (b) a nucleotide sequence having at 
least 90% sequence identity to (a) above; and (c) a nucleotide 
sequence that differs from the nucleotide sequences of (a) or 
(b) above due to the degeneracy of the genetic code. 
Additional aspects of the invention provide an isolated 
nucleic acid encoding a nucleotide sequence selected from 
the group consisting of: (a) the nucleotide sequence encoding 
a polypeptide comprising the amino acid sequence of (1) SEQ 
ID NO:1, (2) SEQID NO:2, (3) SEQ ID NO:3, (4) SEQID 
NO:4, (5) SEQID NO:5 and SEQ ID NO:6, or (6) SEQ ID 
NO:7 and SEQID NO:8; (b) a nucleotide sequence having at 
least 95% sequence identity to (a) above; and (c) a nucleotide 
sequence that differs from the nucleotide sequences of (a) or 
(b) above due to the degeneracy of the genetic code. 
Further aspects of this invention include an isolated nucleic 
acid encoding a nucleotide sequence selected from the group 
consisting of: (a) the nucleotide sequence of SEQID NO:9 or 
SEQID NO:10; (b) a nucleotide sequence having at least 85% 
sequence identity to (a) above; and (c) a nucleotide sequence 
that differs from the nucleotide sequences of (a) or (b) above 
due to the degeneracy of the genetic code. 
Still further aspects of this invention include an isolated 
nucleic acid encoding a nucleotide sequence selected from 
the group consisting of: (a) the nucleotide sequence of SEQ 
IDNO:9 or SEQID NO:10; (b) a nucleotide sequence having 
at least 90% sequence identity to (a) above; and (c) a nucle 
otide sequence that differs from the nucleotide sequences of 
(a) or (b) above due to the degeneracy of the genetic code. 
The present invention further provides an isolated nucleic 
acid encoding a nucleotide sequence selected from the group 
consisting of: (a) the nucleotide sequence of SEQID NO:9 or 
SEQID NO:10; (b) a nucleotide sequence having at least 95% 
sequence identity to (a) above; and (c) a nucleotide sequence 
that differs from the nucleotide sequences of (a) or (b) above 
due to the degeneracy of the genetic code. 
Nucleic acids of this invention can comprise a nucleotide 
sequence that can be identical in sequence to the sequence 
which is naturally occurring or, due to the well-characterized 
degeneracy of the nucleic acid code, can include alternative 
codons that encode the same amino acid as that which is 
found in the naturally occurring sequence. Furthermore, 
nucleic acids of this invention can comprise nucleotide 
sequences that can include codons which represent conserva 
tive Substitutions of amino acids as are well known in the art, 
Such that the biological activity of the resulting polypeptide 
and/or fragment is retained. Additionally, the nucleic acids of 
this invention can also include a nucleic acid strand that is 
partially complementary to a part of the nucleic acid sequence 
or completely complementary across the full length of the 
nucleic acid sequence. Nucleic acid sequences provided 
herein are presented herein in the 5' to 3' direction, from left 
to right and are represented using the standard code for rep 
resenting the nucleotide characters as set forth in the U.S. 
sequence rules, 37 CFRSS 1.821-1.825 and the World Intel 
lectual Property Organization (WIPO) Standard ST.25. 
Accordingly, in Some aspects of the present invention, a 
nucleic acid is provided that encodes a nucleotide sequence 
having a sequence identity in a range from at least 70% to 














the present invention provides a nucleic acid encoding a 
nucleotide sequence having a sequence identity of at least 
70%, at least 75%, at least 80%, at least 81%, at least 82%, at 
least 83%, at least 85%, at least 86%, at least 87%, at least 
88%, at least 89%, at least 90%, at least 91%, at least 92%, at 
least 93%, at least 94%, at least 95%, at least 96%, at least 
97%, at least 98%, at least 99% and/or 100%, and the like, to 
a nucleotide sequence of the present invention. 
Several methods known in the art may be used to produce 
a polynucleotide and/or vector according to this invention. 
A “vector is any nucleic acid molecule for the cloning of 
and/or transfer of a nucleic acid into a cell. A vector may be a 
replicon to which another nucleotide sequence may be 
attached to allow for replication of the attached nucleotide 
sequence. A “replicon' can be any genetic element (e.g., 
plasmid, phage, cosmid, chromosome, viral genome) that 
functions as an autonomous unit of nucleic acid replication in 
vivo, i.e., capable of replication under its own control. The 
term “vector includes both viral and nonviral (e.g., plasmid) 
nucleic acid molecules for introducing a nucleic acid into a 
cell in vitro, ex vivo, and/or in vivo. A large number of vectors 
known in the art may be used to manipulate nucleic acids, 
incorporate response elements and promoters into genes, etc. 
For example, the insertion of the nucleic acid fragments cor 
responding to response elements and promoters into a Suit 
able vector can be accomplished by ligating the appropriate 
nucleic acid fragments into a chosen vector that has comple 
mentary cohesive termini. Alternatively, the ends of the 
nucleic acid molecules may be enzymatically modified or any 
site may be produced by ligating nucleotide sequences (link 
ers) to the nucleic acid termini. Such vectors may be engi 
neered to contain sequences encoding selectable markers that 
provide for the selection of cells that contain the vector and/or 
have incorporated the nucleic acid of the vector into the 
cellular genome. Such markers allow identification and/or 
selection of host cells that incorporate and express the pro 
teins encoded by the marker. A “recombinant vector refers to 
a viral or non-viral vector that comprises one or more heter 
ologous nucleotide sequences (i.e., transgenes), e.g., two, 
three, four, five or more heterologous nucleotide sequences. 
Viral vectors have been used in a wide variety of gene 
delivery applications in cells, as well as living animal Sub 
jects. Viral vectors that can be used include, but are not limited 
to, retrovirus, lentivirus, adeno-associated virus, poxvirus, 
alphavirus, baculovirus, vaccinia virus, herpesvirus, Epstein 
Barr virus, adenovirus, geminivirus, and caulimovirus vec 
tors. Non-limiting examples of non-viral vectors include 
plasmids, liposomes, electrically charged lipids (cytofectins), 
nucleic acid-protein complexes, and biopolymers. In addition 
to a nucleic acid of interest, a vector may also comprise one or 
more regulatory regions, expression control sequences, and/ 
or selectable markers useful in selecting, measuring, and 
monitoring nucleic acid transfer results (e.g., delivery to spe 
cific tissues, duration of expression, etc.). 
Vectors may be introduced into the desired cells by meth 
ods known in the art, e.g., transfection, electroporation, 
microinjection, transduction, cell fusion, DEAE dextran, cal 
cium phosphate precipitation, lipofection (lysosome fusion), 
use of a gene gun, or a nucleic acid vector transporter (see, 
e.g., Wu et al., J. Biol. Chem. 267:963 (1992); Wu et al., J. 
Biol. Chem. 263: 14621 (1988); and Hartmut et al., Canadian 
Patent Application No. 2,012,311, filed Mar. 15, 1990). 
In some embodiments, a polynucleotide of this invention 
can be delivered to a cell in vivo by lipofection. Synthetic 
cationic lipids designed to limit the difficulties and dangers 
encountered with liposome-mediated transfection can be 
used to prepare liposomes for in vivo transfection of a nucle 
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otide sequence of this invention (Feigner et al., Proc. Natl. 
Acad. Sci. USA 84:7413 (1987); Mackey, et al., Proc. Natl. 
Acad. Sci. U.S.A. 85:8027 (1988); and Ulmer et al., Science 
259: 1745 (1993)). The use of cationic lipids may promote 
encapsulation of negatively charged nucleic acids, and also 
promote fusion with negatively charged cell membranes 
(Feigner et al., Science 337:387 (1989)). Particularly useful 
lipid compounds and compositions for transfer of nucleic 
acids are described in International Patent Publications 
WO95/18863 and WO96/17823, and in U.S. Pat. No. 5,459, 
127. The use of lipofection to introduce exogenous nucleotide 
sequences into specific organs in vivo has certain practical 
advantages. Molecular targeting of liposomes to specific cells 
represents one area of benefit. In representative embodi 
ments, transfection is directed to particular cell types in a 
tissue with cellular heterogeneity, Such as pancreas, liver, 
kidney, and the brain. Lipids may be chemically coupled to 
other molecules for the purpose of targeting (Mackey, et al., 
1988, Supra). Targeted peptides, e.g., hormones or neu 
rotransmitters, and proteins such as antibodies, or non-pep 
tide molecules can be coupled to liposomes chemically. 
In various embodiments, other molecules can be used for 
facilitating delivery of a nucleic acid in vivo, Such as a cat 
ionic oligopeptide (e.g., WO95/21931), peptides derived 
from nucleic acid binding proteins (e.g., WO96/25508), and/ 
or a cationic polymer (e.g., WO95/2 1931). 
It is also possible to introduce a vector in vivo as naked 
nucleic acid (see U.S. Pat. Nos. 5,693,622, 5,589,466 and 
5,580,859). Receptor-mediated nucleic acid delivery 
approaches can also be used (Curiel et al., Hum. Gene Ther. 
3:147 (1992); Wu et al., J. Biol. Chem. 262:4429 (1987)). 
The term “transfection' or “transduction' means the 
uptake of exogenous or heterologous nucleic acid (RNA and/ 
or DNA) by a cell. A cell has been “transfected' or “trans 
duced with an exogenous or heterologous nucleic acid when 
such nucleic acid has been introduced or delivered inside the 
cell. A cell has been “transformed by exogenous or heter 
ologous nucleic acid when the transfected or transduced 
nucleic acid imparts a phenotypic change in the cell and/or a 
change in an activity or function of the cell. The transforming 
nucleic acid can be integrated (covalently linked) into chro 
mosomal DNA making up the genome of the cell or it can be 
present as a stable plasmid. 
In other aspects of the invention, a composition is provided 
comprising an isolated polypeptide of the present invention in 
a pharmaceutically acceptable carrier. Another aspect of the 
invention is a composition comprising an isolated nucleic 
acid of the invention in a pharmaceutically acceptable carrier. 
In some embodiments of the present invention, the com 
positions of the present invention can be useful in treatment or 
prevention of diseases and disorders. In other embodiments, 
the compositions of the invention are useful for treatment or 
prevention of a cosmetic condition in a Subject. In some 
particular aspects of the present invention a method is pro 
vided for treating spasmodic muscles in a Subject, said 
method comprising administering to said Subject an effective 
amount of a composition of the present invention as described 
herein. 
In other embodiments, a composition of the present inven 
tion as described herein, can be used to treat diseases or 
disorders including, without limitation, Strabismus (crossed 
or misaligned eyes), blepharospasm (eyelid spasms), hemi 
facial spasm (unilateral muscle contractions of the face), 
headache pain including pain due to a migraine headache, 
cervical dystonia, primary axillary hyperhidrosis (excessive 
underarm Sweating), palmar hyperhidrosis, prostatic symp 













post stroke spasticity, diabetes, obstructive pulmonary dis 
ease, achalasia (esophageal motility disorder), chronic 
obstructive pulmonary disease (COPD), back pain, cerebral 
palsy including but not limited to pediatric spastic cerebral 
palsy, chronic anal fissure, delayed gastric emptying, dyspho 
nia including but not limited to spasmodic dysphonia and/or 
oromandibular dysphonia, epilepsy, epiphora, esotropia, 
essential tremor, eye lift, facial myokemia, fibromyalgia, 
flushing, Grey's syndrome, musculoskeletal pain syndromes, 
pancreatitis, Parkinson's disease, puborectalis syndrome, 
rhinitis, sialorrhea, tardive dyskinesia, tennis elbow, 
Tourette's syndrome, urinary incontinence, vaginismus, writ 
er's cramp, laryngeal dystonia, lingual dystonia, cervical dys 
tonia, focal hand dystonia, blepharospasm, anismus, hemifa 
cial spasm, focal spasticity, spasmodic colitis, neurogenic 
bladder, limb spasticity, tics, bruxism, dysphagia, lacrima 
tion, excessive salivation, excessive gastrointestinal secre 
tions, as well as other secretory disorders, pain from muscle 
spasms and the like (see, Cheng et al. Amer. J. Health-Syst. 
Pharm. 63:145-152 (2006) and U.S. Pat. No. 6,908,925). 
Thus, in Some aspects of the invention, a method of treating 
and/or preventing a disorder in a subject is provided, com 
prising administering to the Subject an effective amount of a 
composition of the present invention as described herein, 
wherein the disorder is selected from the group consisting of 
Strabismus (crossed or misaligned eyes), blepharospasm 
(eyelid spasms), hemifacial spasm (unilateral muscle con 
tractions of the face), headaches including migraine head 
aches, cervical dystonia, primary axillary hyperhidrosis (ex 
cessive underarm Sweating), palmar hyperhidrosis, prostatic 
symptoms including but not limited to benign prostatic hyper 
plasia, asthma, stroke symptoms, diabetes, obstructive pull 
monary disease, achalasia (esophageal motility disorder), 
chronic obstructive pulmonary disease (COPD), back pain, 
cerebral palsy including but not limited to pediatric spastic 
cerebral palsy, chronic anal fissure, delayed gastric emptying, 
dysphonia including but not limited to spasmodic dysphonia 
and/or oromandibular dysphonia, epilepsy, epiphora, esotro 
pia, essential tremor, eye lift, facial myokemia, fibromyalgia, 
flushing, Grey's syndrome, musculoskeletal pain syndromes, 
pancreatitis, Parkinson's disease, puborectalis syndrome, 
rhinitis, sialorrhea, tardive dyskinesia, tennis elbow, 
Tourette's syndrome, urinary incontinence, vaginismus, writ 
er's cramp, laryngeal dystonia, lingual dystonia, cervical dys 
tonia, focal hand dystonia, blepharospasm, anismus, hemifa 
cial spasm, focal spasticity, spasmodic colitis, neurogenic 
bladder, limb spasticity, tics, bruxism, dysphagia, lacrima 
tion, excessive salivation, excessive gastrointestinal secre 
tions, as well as other secretory disorders, and pain from 
muscle spasms. 
In other aspects of the invention, the cosmetic conditions 
for which the compositions of the present invention can be 
useful include, but are not limited to, the prevention and/or 
treatment of wrinkles and fine lines in the skin of a subject. 
Such treatments of the skin of a subject include without 
limitation the treatment of the face and neck. In some embodi 
ments of the invention, Such treatments include, but are not 
limited to, frown wrinkles, forehead wrinkles, lateral canthal 
wrinkles (“crow’s feet”), brow furrows, nose crease wrinkles, 
wrinkles around the mouth and ears. In some embodiments of 
the invention, the treatment includes treatment of the cutane 
ous skin tissue of the Subject, and in other embodiments, the 
treatment includes treatment of the Subcutaneous skin tissue 
of the subject. Treatments of the skin of the face and neck as 
described above of minimize of appearance of for example, 
frown wrinkles, forehead wrinkles, lateral canthal wrinkles 
(“crow’s feet”), brow furrows, nose crease wrinkles, wrinkles 
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around the mouth and ears, over time (e.g., days, weeks, 
months, years) as compared to the absence of treatment with 
the compositions of the present invention. 
Thus, in Some embodiments, the present invention pro 
vides a composition comprising, consisting essentially of 
and/or consisting of a protein and/or nucleic acid of this 
invention in a pharmaceutically acceptable carrier and, 
optionally, further comprising other medicinal agents, phar 
maceutical agents, stabilizing agents, buffers, carriers, adju 
vants, diluents, etc. In other embodiments, the compositions 
of the present invention comprise a safe and effective amount 
of the active agents, and a cosmetically acceptable carrier. 
The phrase "cosmetically acceptable carrier, as used herein, 
means any Substantially non-toxic carrier Suitable for admin 
istration to the skin, which has good aesthetic properties, and 
is compatible with the active agent of the present invention. 
By “compatible' it is meant that the active agent will remain 
stable and retain substantial activity therein. The carrier can 
be in a wide variety of forms, such as sprays, emulsions, 
mousses, liquids, creams, oils, lotions, ointments, gels and 
Solids. 
For injection, the carrier will typically be a liquid. For other 
methods of administration, the carrier may be either solid or 
liquid. For inhalation administration, the carrier will be respi 
rable, and will preferably be in solid or liquid particulate form 
(e.g., powder). Further provided herein is a pharmaceutical 
composition comprising a protein or active fragment thereof 
of this invention in a pharmaceutically acceptable carrier. 
Additional compositions of this invention can include any of 
the proteins, active fragments and/or nucleic acids of this 
invention in any combination, in a pharmaceutically accept 
able carrier. 
"Pharmaceutically acceptable as used herein, means a 
material that is not biologically or otherwise undesirable, i.e., 
the material may be administered to an individual along with 
the compositions of this invention, without causing Substan 
tial deleterious biological effects or interacting in a deleteri 
ous manner with any of the other components of the compo 
sition in which it is contained. The material would naturally 
be selected to minimize any degradation of the active ingre 
dient and to minimize any adverse side effects in the Subject, 
as would be well known to one of skill in the art (see, e.g., 
Remington's Pharmaceutical Science; latest edition). Exem 
plary pharmaceutically acceptable carriers for the composi 
tions of this invention include, but are not limited to, sterile 
pyrogen-free water and sterile pyrogen-free physiological 
saline Solution. 
A “subject' of this invention includes any subject that is 
Susceptible to the various diseases, disorders and/or cosmetic 
conditions described herein. Nonlimiting examples of sub 
jects of this invention include mammals, such as humans, 
nonhuman primates, domesticated mammals (e.g., dogs, cats, 
rabbits, guinea pigs, rats), livestock and agricultural mam 
mals (e.g., horses, bovine, pigs, goats). In other embodi 
ments, a Subject may additionally be an animal Such as a bird 
or reptile. Thus, in some embodiments, a Subject can be any 
domestic, commercially or clinically valuable animal. Sub 
jects may be male or female and may be any age including 
neonate, infant, juvenile, adolescent, adult, and geriatric Sub 
jects. In particular embodiments, the Subject is a human. A 
human Subject of this invention can be of any age, gender, 
race or ethnic group (e.g., Caucasian (white), Asian, African, 
black, African American, African European, Hispanic, Mid 
eastern, etc.). 
A subject of this invention can be “in need of the methods 
of the present invention, e.g., because the Subject has, or is 














disorder and/or cosmetic condition including those described 
herein and/or is a subject that would benefit from the methods 
of this invention. For example, a subject in need of the meth 
ods of this invention can be, but is not limited to, a subject 
diagnosed with, having or Suspected to have, or at risk of 
having or developing Strabismus (crossed eyes). 
A further aspect of the invention is a method of adminis 
tering or delivering a Scorpion protease polypeptide of the 
invention, a fragment thereof, and/or a nucleic acid encoding 
the same, to a subject of this invention. Administration or 
delivery to a human Subject or an animal in need thereof can 
be by any means known in the art for administering polypep 
tides, protein fragments and/or nucleic acids. In some 
embodiments, a polypeptide, fragment thereof and/or nucleic 
acid is delivered in a therapeutically effective dose in a phar 
maceutically acceptable carrier. 
In embodiments in which a nucleic acid of this invention is 
delivered in a viral vector (e.g., a virus particle), the dosage of 
virus particles to be administered to a subject will depend 
upon the mode of administration, the disease or condition to 
be treated, the individual subjects condition, the particular 
virus vector, and the nucleic acid to be delivered, and can be 
determined in a routine manner. Exemplary doses are virus 
titers of at least about 10, 10, 107, 10, 10, 10', 10'', 10', 
10, 10", 10' transducing units or more, preferably about 
10-10' transducing units, yet more preferably 10' trans 
ducing units. 
Additional non-limiting exemplary modes of administra 
tion of the proteins, nucleic acids and vectors of this invention 
can include oral, rectal, transmucosal, topical, intranasal, 
inhalation (e.g., via an aerosol), buccal (e.g., Sublingual), 
vaginal, intrathecal, intraocular, transdermal, in utero (or in 
ovo), parenteral (e.g., intravenous, Subcutaneous, intrader 
mal, intramuscular including administration to facial, neck, 
skeletal, diaphragm and/or cardiac muscle, intradermal, 
intrapleural, intracerebral, and intraarticular), topical (e.g., to 
both skin and mucosal Surfaces, including airway Surfaces, 
and transdermal administration, and the like, as well as direct 
tissue or organ injection (e.g., to liver, skeletal muscle, car 
diac muscle, diaphragm muscle or brain). Administration can 
also be to a tumor (e.g., in or a near a tumor oralymph node). 
The most Suitable route in any given case will depend on the 
nature and severity of the condition being treated and on the 
nature of the particular protein, peptide, fragment, nucleic 
acid or vector that is being used. 
Thus, in some aspects of the invention, depending on the 
mode of administration that is to be used, the compositions 
can be in a form including, but not limited to liquid, gel. 
cream, foam, ointment, aerosol, capsule, fluid, powder, semi 
Solid formulation (e.g., Suppository) and/or the like. 
Dosages of the polypeptides and/or active fragments 
thereof and/or nucleic acids encoding the same, to be admin 
istered to a subject will depend upon the mode of administra 
tion, the disease or condition to be treated, the individual 
Subject's condition including, but not limited to, age and 
weight, the particular polypeptide and/or active fragment 
and/or nucleic acid encoding same, and any other agents 
being administered to the Subject and can be determined in a 
routine manner according to methods well known in the art. In 
Some embodiments, an exemplary dosage range is from about 
0.001 unit to about 10,000 units. In other embodiments, the 
dosage range can be from about 100 units to about 10,000 
units. In still other embodiments, the dosage range can be 
from about 0.01 unit to about 5000 units. In yet further 
embodiments, the dosage range can be from about 1 unit to 
about 5000 units. In some embodiments, the dosage range can 
be from about 10 units to about 1000 units. In other embodi 
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ments, the dosage range can be from about 100 units to about 
500 units. In still other embodiments, the dosage range can be 
from about 20 units to about 100 units. Units are LDs units 
determined using 20-30g Swiss-Webster mice (see, e.g., U.S. 
Pat. No. 7,494,661 and U.S. Pat. No. 7,491,403) 
Although examples of routes of administration and dos 
ages are provided, the appropriate route of administration and 
dosage are generally determined on a case by case basis by the 
attending physician. Such determinations are routine to one 
of ordinary skill in the art (see for example, Harrison's Prin 
ciples of Internal Medicine (1998), edited by Anthony Fauci 
et al., McGraw Hill 14th edition). 
In particular embodiments, more than one administration 
(e.g., two, three, four or more administrations) of the 
polypeptide, fragment and/or nucleic acid of this invention 
may be employed to achieve the desired result over a period of 
various intervals, e.g., daily, weekly, monthly, yearly, etc. 
The present invention will now be described with reference 
to the following examples. It should be appreciated that these 
examples are for the purpose of illustrating aspects of the 
present invention, and do not limit the scope of the invention 




Caerulein was a gift from Dr. J. Jamieson, Yale University 
(New Haven, Conn.). Whole dried Tityus serrulatus (Lutz and 
Mello) scorpion venom was from the Instituto Butantan, Sao 
Paulo, Brazil. Toxin Y, Fractions v and were prepared as 
previously described (17). Centruroides sculpturatus (Ew 
ing) scorpion venom was the gift of Dr. Dean Watt, Creighton 
University (Omaha, Nebr.). N-isopropyliodo-acetamide was 
a gift from Dr. J. Inman, NIH. H4 ProteinChips and the 
calibration standard molecules for the SELDI-TOF mass 
spectrometer were purchased from Ciphergen Biosystems 
Inc. (Fremont, Calif.). C.-Cyano-4-hydroxy-cinnamicacid 
(CHCA), Sinapinic acid (SA), iodoacetic acid (IAA), and 
angiotensin were obtained from Sigma (St. Louis, Mo.). The 
peptide calibration kit was purchased from Ciphergen. H4 
ProteinChips and the calibration standard molecules for the 
SELDITOF mass spectrometer were purchased from Cipher 
gen BioSystems Inc. (Fremont, Calif.). C.-Cyano-4-hydroxy 
cinnamic acid (CHCA). Sinapinic acid (SA), iodoacetic acid 
(IAA), and angiotensin were obtained from Sigma (St. Louis, 
Mo.). N-isopropyliodo-acetamide was a gift from Dr. J. 
Inman, NIH. 
Animal 
Dunkin-Hartley guinea pigs were used for collection of 
pancreatic lobules for in vitro experiments as described (16). 
Protocols for animal tissue studies were approved by the East 
Carolina University Institutional Animal Care and Use Com 
mittee. 
Example 2 
Pancreatic Lobule Experiments 
Published protocols were followed for the radiolabeled 
secretion dose-response assays (16, 17). For Western blots, 
excised lobules were prepared using the Institutional Animal 
Care and Use Protocols. Incubations in Krebs Ringer Bicar 
bonate (KRB) under various conditions and times in vitro 













were homogenized in 25 mM HEPES buffer, pH 6.8, with 
protease inhibitors (27), then stored at -20°C. Protein con 
centration was determined using the bicinchoninic acid 
(BCA) assay (Pierce Chemical Co., Rockford, Ill.). 
Pancreatic lobules were pulsed with H-leucine for 10 min 
at 37°C. in KRB, then rinsed. Chase-incubation followed for 
3 h, then the lobules were homogenized. TCA-precipitable 
protein samples were processed for Scintillation counting. 
Average resting secretion in untreated control lobules was 
7.1%. (FIG. 1A). 
Western blots were prepared for VAMP2 and VAMP8 
using lobules incubated in KRB in vitro at 37° C. for 3 hours 
in optimal stimulatory doses for carbachol (CARB) (10 uM) 
and caerulein (CAER) (1 nM) and hyperstimulatory Tx Y 
(secretagogue toxin gamma) dose (100 nM). Following the 
incubation, the lobules were homogenized. Homogenate 
samples (20 ug/lane) were subjected to SDS-polyacrylamide 
gel electrophoresis (PAGE) and then transblotted. (FIGS. 1B, 
1C, 1D). For samples in FIGS. 1B, 1C, and 1D, n=4 or 2 
experiments with duplicate flasks. 
Example 3 
Electron Microscopic (EM) Immunocytochemistry 
Lobules were diced into about 2 mm pieces and fixed in 
0.25% glutaraldehyde (Polysciences, Warrington, Pa.)—4% 
paraformaldehyde (EMS, Hatfield, Pa.) in 0.1 M sodium 
cacodylate buffer, pH 7.4, at 4°C. overnight. Embedment was 
in LR White, a low viscosity acrylic embedding medium, 
(Polysciences, Warrington, Pa.) with thermal cure. Thin sec 
tions of 90 nm were collected on Formvar-coated nickel grids. 
Nonspecific binding was blocked by pre-treatment in 5% 
normal goat serum (NGS). Grids were then incubated over 
night at 4°C. in polyclonal VAMP2 primary antibody (1:50) 
(Stressgen, Victoria, BC, Canada). To confirm specific label 
ing, Some grids were incubated as negative controls in PBS/ 
1% NGS without primary antibody. After rinsing with PBS, 
grids were transferred to 10 nm gold conjugated goat anti 
rabbit IgG secondary antibody (1:100) (British Biocell Inter 
national, Ted Pella, Inc., Redding, Calif.) for 1 h. Grids were 
stained in 4% aqueous uranyl acetate (EMS, Hatfield, Pa.). 
Sections were examined in a JEOL 1200EX electron micro 
Scope equipped withiTEM digital image acquisition Software 
(Soft Imaging System GmbH, Munster, Germany). 
Morphometric image analysis was conducted with iTEM. 
Results represent two experiments and five immunogold 
incubations. 
Example 4 
Isolation of Zymogen Granules and Membranes 
Zymogen granules (ZG) and their membranes (ZGM) were 
prepared according to the method of Meldolesi et al. (28) and 
stored at -80° C. in protease inhibitor buffer (27). Briefly, ZG 
were purified from guinea pig pancreas homogenates by dif 
ferential centrifugation. ZGM were prepared from lysed ZG. 
Protein concentration was measured with the BCA protein 
assay. 
Example 5 
Electrophoresis and Blotting 
Pancreatic homogenates, ZG, or ZGM (20-25 ug protein/ 
lane) or recombinant SNARE proteins (10-90 uM) were sepa 
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rated by PAGE on 14% SDS Laemmligels then electroblotted 
to PVDF (Polyvinylidene Difluoride) membranes. Visualiza 
tion of bound conjugate on Western blots was by colorimetric 
staining. Primary antibodies were: polyclonal VAMP2 
(Stressgen, Victoria, BC, Canada), VAMP3 (Abeam, Cam 
bridge, Mass.), VAMP8 (Synaptic Systems, Gottingen, Ger 
many), monoclonal PY20 (BD Transduction Labs, Lexing 
ton, Ky.). Secondary antibodies were anti-mouse IgG alkaline 
phosphatase conjugate and anti-rabbit IgG alkaline phos 
phatase conjugate (Promega Corp., Madison, Wis.). Trans 
blot membranes were developed with 0.1% Coomassie blue 
R stain. Both Western blots and transblots were routinely 
repeated a minimum of three times per experiment. Images 
shown are representative of these. 
Example 6 
Gel Filtration 
Whole dried scorpion venom (500 mg) was solubilized 
then applied to a Sephadex G-50 column (Superfine) (2.5x 
100 cm) as described (17). Fractions (5 ml) were collected, 
pooled, and freeze dried. 
Example 7 
Reverse Phase Chromatography 
Reverse phase chromatography was carried out using a 
Vydac 254TP54Cs column. Elution utilized a linear gradi 
ent to 60% acetonitrile with 0.1% trifluoroacetic acid (TFA) 
and uniform flow rate of 1.0 ml/min. Detection followed 
absorbance recording at both 280 and 215 nm. Resolved 
components were collected accordingly. 
Example 8 
Amino Acid Sequence Analysis 
Protein samples were hydrolyzed in evacuated and sealed 
Pyrex glass tubes with 200 ul 6N HCl with 0.5% phenol 
heated to 110°C. for 20h. Hydrolyzed samples were stored at 
-20°C. until time for analysis when hydrolysis solution was 
removed in a vacuum centrifuge (Savant SpeedVac, Hicks 
ville, N.Y.). The dried samples were dissolved in sample 
buffer (0.2 MSodium citrate, pH 2.2) and then loaded into the 
injection loop to initiate analysis. Analysis was carried out in 
a Dionex BioLC Amino Acid Analyzer utilizing a ninhydrin 
detection system and AI450 instrument control and data man 
agement System. 
Chromatographic peaks were manually collected and Vol 
ume was reduced by evaporation in a Savant SpeedVac cen 
trifuge followed by storage at -20°C. The peptide cleavage 
products of VAMP2 by Fx v metalloprotease, separated by 
reverse phase chromatography, were transferred to a Beck 
man peptide disk. These peptides and others isolated from 
cleavage products of the metalloprotease were sequenced on 
an ABI Procise Model 492 using the pulsed liquid protocol 
and PTH-amino acids identified by on-line analysis based on 
a 10-pmol PTH standard. 
Example 9 
Surface-Enhanced Laser Desorption/Ionization Time 
Offlight (SELDI-TOF) Mass Spectrometry 
The SELDI-TOF mass spectrometer was externally cali 













1084.24 m/z, human ACTH 1-24 at 2933.50 m/z, bovine 
insulin B chain at 3495.94 m/z, human recombinant insulinat 
5807.65 m/z, and hirudin BKHV at 7033.61 m/z. All mass 
spectra were recorded in the positive-ion mode using a 
Ciphergen PBS II ProteinChip Array reader, a linear laser 
desorption/ionization-time of flight mass spectrometer with 
time-lag focusing (29). Prior to SELDI-TOF MS analysis, 1 
ul of matrix (saturated CHCA in 50% aqueous acetonitrile 
containing 0.1% TFA was added to each feature of Protein 
Chip Surface for the analysis. Raw data were analyzed using 
the computer software provided by the manufacturer and are 
reported as average masses. 
Example 10 
BioInformatics and Molecular Modeling 
Insight|I (Accelrys, Inc., San Diego, Calif.) and Pymol 
(Delano Scientific LLC, Palo Alto, Calif.)) was used to extend 
the molecular structures and homology of coiled-coil 
SNARE crystallography (1sfc.pdb.) to provide a model for 
VAMP2. 
Example 11 
SNARE Cloning, Expression, Purification, and 
Characterization 
Plasmids, protein expression, and protein purification for 
full-length SNAP25A, truncated VAMP2 (1-94 and 1-96: 
Rattus norvegicus) and syntaxin1 A (1-263), have been 
described previously (30-34). The VAMP8 plasmid (1-74; 
Rattus norvegicus) was a kind gift from Dr. Gottfried Mieskes 
(Max Planck Institute for Biophysical Chemistry). All pro 
teins were expressed individually in Escherichia coli BL21 
(DE3) in Terrific Broth media as 6-His fusions in the pet28a 
vector (Novagen, Gibbstown, N.J.) except VAMP2 (1-94), 
which was from the pGEX-4T vector (G.E. Biosciences), as 
described (35-37). All 6-His tagged proteins were initially 
purified via Ni-nitrilotriacetic acid (NTA) agarose (Qiagen, 
Germantown, Md.) according to manufacturers instructions 
using native conditions for the syntaxin and SNAP25 and 
denaturing protocols for VAMP2 and VAMP8. VAMP2 and 
VAMPS were extensively dialyzed into native condition 
buffer (50 mM Phosphate, pH 8.0, 300 mM. NaCl, 1 mM 
DTT) before further use. VAMP2 (1-94) was purified by 
glutathione Sepharose 4B (Amersham Biosciences, Piscat 
away, N.J.) according to manufacturers instructions. Syn 
taxin and SNAP25 were further purified by anion exchange 
chromatography on monoC resin (GE Biosciences, Piscat 
away, N.J.) in 20 mM Tris-HCl, pH 8.2, with elutionina NaCl 
gradient. The mutations in VAMP2, changing residues E41 to 
C41, K85 to A85, R86 to S86 and K87 to A87, were intro 
duced into the VAMP2 plasmid using the Quickchange 
method (Stratagene, Wilmington, Del.) and were verified by 
sequencing the gene in the final plasmid. The triple mutant 




Recombinant SNARE proteins were incubated in PBS, pH 
7.4, with 1.0 mMZnCl2 and 1.0 mM CaCl for specified times 
at 37°C. in a water bath with agitation. 
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Example 13 
SNARE Complex Assembly 
The ternary SNARE complex was assembled and purified 
as described previously (310). Briefly, SNARE complexes 
were formed by adding SNAP25 to syntaxin followed by the 
addition of VAMP2 (35-37) in a ratio of 1:2:3 (syntaxin: 
SNAP25:VAMP2), generating SDS resistant SNARE com 
plexes (38). SNARE complex assembly was carried out in 20 
mM Tris-HCl, pH 8.2, 200 mM. NaCl (TBS) by first incubat 
ing at 42°C. for 1.5 h and then 4°C. for 12 h. For the purpose 
of additional purification of the assembled complex, the his 
tidine tag was not cleaved from VAMP2 but was removed by 
thrombin treatment from syntaxin and SNAP25 before 
assembly. The assembly reaction was rebound to Ni-NTA 
agarose after the 12 h incubation, extensively washed with 
TBS to remove excess syntaxin and SNAP25, and eluted in 
TBS containing 200 mMimidazole. The assembled complex 
was then rebound to monoC resin. VAMP2 (1-96) does not 
bind monoQ under loading conditions so excess VAMP2 
flows through. The purified ternary SNARE complex was 
then eluted in a NaCl gradient. 
Example 14 
Pancreatic Exocrine Regulated Secretion and 
SNARE Proteins 
The exocrine pancreas has great protein biosynthetic 
capacity as well as the ability to store large quantities of 
proteins for regulated secretory discharge upon presentation 
of the proper secretory agonist. The basic unit of this tissue, 
the pancreatic acinar cell, produces and stores exocrine pro 
teins in Vesicular elements in the trans-Golgi network that 
become mature Zymogen or secretory granules positioned 
near or at the apical plasmallemma. Docking and fusion events 
have been shown to utilize the SNARE family of proteins to 
vectorially transport secretory proteins from endoplasmic 
reticulum through Golgi processing to apical discharge stages 
of these relatively large granules (>0.5um) (39). 
Experimental protocols were designed to differentially 
characterize stimulation from Scorpion Venom secretagogues 
in comparison with classical cholinergic (carbachol) and pep 
tidergic (caerulein) secretagogues. Tissues treated with these 
Venom preparations produce linear dose response curves 
similar to carbachol and caerulein only up to a level of venom 
of 1 g/ml (FIG. 1A). Protein discharge is diminished at 
higher levels of venom (16, 20). The TSV plot shown is 
similar to one previously published (16) and is included only 
for comparison and reference. 
Example 15 
Scorpion Venom (TSV) Stimulates Pancreatic 
Exocrine Secretion and Cleaves VAMP SNARES 
Experiments were carried out at the optimum dose-re 
sponse level (1 g/ml) to produce maximal secretion, and at 
hyperstimulatory amounts of TSV (Tityus serrulatus venom) 
(5 g/ml and 50 g/ml). Both positive stimulated (carbachol 
and caerulein) and unstimulated controls were included 
(FIGS. 1B and 1D)). 
PY20 Western blots reveal part of the pattern of phospho 
rylation of tyrosine (Tyr) residues (PY20) of proteins in tissue 
homogenates of guinea pig pancreatic lobules (incubated for 














nificant bands indicating Tyr phosphorylation in pancreatic 
homogenates were prominent at 17 kDa in control tissue. 
Samples that included the lowest concentration (1 lug/ml) of 
TSV appeared the same as control samples. At the highest 
venom levels (5 and 50 g/ml) a different pattern emerged. 
Appearance of bands at 14 and 12 kDa and the concomitant 
disappearance of the 17 kDa band coinciding with higher 
concentrations of TSV indicated proteolysis. Bands from 
Venom treated tissue showed marked decreases as quickly as 
5 min, even at 4°C. (FIG.1C). Crude membrane preparations 
showed the same patterns but post microsomal Supernates did 
not (not shown). The PY20-positive band of 17 kDa was 
tentatively identified as Vesicle Associated Membrane Pro 
tein (VAMP) because of the apparent molecular weight simi 
larities and membrane association. Samples were probed 
with anti-VAMP antisera (FIG. 1E) that provided putative 
identity as VAMP2 (2 Tyr residues) or VAMP3 (1 Tyr resi 
due). FIG. 1D shows that none of the classical secretagogues 
(carbachol and caerulein) or the Venom secretagogue toxin 
gamma (TX Y) cause tissue alterations during a 3 h incubation, 
while TSV cleaves the native V-SNAREs, VAMP2 and 
VAMPS. 
Example 16 
Identification of a Proteolytic Fraction in TSV 
Isolation of a potential venom protease activity involves 
systematic purification stages. Using Sephadex G-50 and in 
vitro incubations with recombinant VAMP2, the proteolytic 
activity in Fx v was found in the highest molecular weight 
fraction. Assays of Fx v for stimulation of radiolabeled 
(newly-synthesized) proteins revealed weak secretory activ 
ity that is diminished in comparison with TSV (FIG. 1A). 
This fraction is known to have limited or no animal toxicity. 
Fx that follows chromatographically is the next lower 
molecular weight fraction and has stronger secretagogue 
activity (FIG. 1A); however, no proteolytic activity was 
detectable. 
Example 17 
Electron Microscopy Shows VAMP2 Destruction 
Excised guinea pig pancreatic lobules were incubated in 
vitro with a hyperstimulatory dose of TSV (50 ug/ml) for 1 h 
at 37°C., rinsed in KRB, then prepared for electron micros 
copy (EM). Untreated (control) lobules were incubated in 
KRB alone. Thin sections were probed with primary antisera 
against VAMP2, then labeled with secondary antibodies con 
jugated with gold (Au) nanoparticles (10 nm) to detect bound 
immunoglobulins. Examples of these sections are seen in 
FIGS. 2A and 2B. Immunocytochemistry of tissues treated in 
vitro shows decreased colloidal gold labeling in VAMP2, 
mainly associated with mature ZG, as a result of apparent 
Venom proteolytic activity. 
Because the epitope for this antigen in the TSV-treated 
tissue in FIG. 2B has significantly fewer Au nanoparticles 
than the control cells (FIG. 2A), the conclusion is that cleav 
age of VAMP2 has occurred. These EM immunogold studies 
provide structural verification of the biochemical findings 
seen in FIG. 1C. A separate experiment extending incubation 
to 3 h with 100 g/ml TSV documented the same reduction of 
VAMP2 Au particles. 
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Example 18 
TSV and Fx v Degrade VAMP2 and VAMP8 in 
Isolated Zymogen Granules and Zymogen Granule 
Membranes 
Sub-cellular fractionation was carried out to distinguish 
organelles and membrane systems from cytoplasmic pro 
teins. Zymogen granules (ZG) and their isolated membranes 
(ZGM) provided significantly less protein diversity; however, 
the alterations produced by exposure to venom in vitro 
remained constant. As indicated in FIG.3, isolated ZG devel 
oped cleavages similar to those in pancreatic lobules. TSV 
produced cleavages in VAMP2 in both ZG (FIG. 3A) and 
ZGM (FIG. 3B). As seen in FIG. 3C, VAMP8 is also a pro 
teolytic target in ZG during incubation with FX v. FIG. 3D 
shows that whole TSV or Fx v rapidly cleave VAMP2 (upper 
panel) even in short incubation periods (5 and 30 min). The 
PY20 immunoblots (lower panel) parallel this result and are 
probably reflective of VAMP2 because VAMP8 has no 
tyrosine residues (see FIG. 6). Carbachol, caerulein and Tx Y 
do not cause cleavage of VAMP2 in ZG and these patterns are 
the same as the control in Western blots. 
By limiting the source of cellular proteins to the ZG and 
ZGM, the range of potential cleavage targets was further 
limited. ZGM include small amounts of VAMP2, known to 
have a blocked (acetyl) N-terminus, as well as VAMP8 and 
other similar sized proteins (40). The cleavages produced 
using these substrates were not sufficient to provide a defini 
tion for the site of attack. Interference from integral ZGM 
proteins and retained cytoplasmic and Zymogen proteins pre 
vented assignment of a precise cleavage site with in vitro 
experiments using tissue Sub-fractions. Based upon apparent 
localization and molecular weight, a source of pure cytoplas 
mic protein substrate, recombinant VAMP2, was investi 
gated. 
Example 19 
Recombinant VAMP2 Provides Proteolytic Target 
Identification 
To confirm substrate identity and reveal cleavage site both 
whole venom and chromatographically purified venom pro 
teins were employed with a bacterially expressed, recombi 
nant version of the truncated soluble WTVAMP2 (amino 
acids 1-94) protein as substrate. VAMP2 or a modified 
VAMP2 (E41C) was incubated with TSV, Fx v or FX at 37° 
C. for 30 min. FIG. 4A (left panels) shows that these VAMP2 
substrates are cleaved by TSV. The middle and right panels of 
FIG. 4A show that Fx v produces VAMP2 cleavage under 
these conditions but Fx w causes no proteolysis. FIG. 4D 
reveals a potential cleavage product band, differing from the 
Substrate protein by approximately 2 kDa, that appears after 5 
minincubation with Fx v, then becomes more prominent until 
120 min, and is evident only faintly at 180 min. Substrate 
bands diminish at all time points with the exception of the 
undigested control samples that retain original density. 
Results presented in FIG. 4D include both transblots as well 
as Western blots probed for VAMP2. Bands shown in the 
transblots and Western blots reveal similar outcomes. In addi 
tion, the immunoblots visualize another band at 6 kDa. Simi 
lar results were observed with the 1-96 fragment of VAMP2. 













sculpturatus, was tested and its proteolytic activity with 
VAMP2 Substrate is shown in FIG. 4E. 
Example 20 
Fx v Proteolysis of VAMP2 Requires Divalent 
Cations 
Primary structure determinations of the isolated venom 
proteases reveal a putative divalent cation binding site. The 
sequence (HESVHLLGSPHD; SEQID NO: 7) that is iden 
tified is a recognized motif for Zinc binding (41). With this 
information, experiments were designed to examine the 
effects of divalent cation chelation on the protease activity of 
the enzymes. 
Fx v was pre-incubated with 10 mM EDTA for 60 min prior 
to addition of 10 uM WTVAMP2 (1-94) or VAMP2 variant 
(E41C) substrate. This chelation step was sufficient to prevent 
detectable VAMP2 cleavage by Fx v after 60 minat 37° C. as 
shown in FIG. 4B. Thus, these experiments further confirm 
the metalloprotease nature of the FX v proteases of the present 
invention. 
Example 21 
Amino Acid Substitutions at the VAMP2 Cleavage 
Site Prevent Proteolysis 
Amino terminal sequencing of VAMP2 reveal that the 
major proteolytic bands make up the majority of this protein 
(residues 1-87) and that the smaller cleaved carboxyl termi 
nus is not recovered due to its short sequence (88-94) of seven 
residues. Reverse phase chromatography of aliquots of the 
digestion mixtures provided cleaved peptides of both amino 
and carboxyl termini as determined by protein sequencing 
(FIG. 5A). Cleavage peptides that were recovered and 
sequenced indicated enzymatic hydrolysis with new amino 
termini at residues K85, R86 and K87. These peptides 
revealed a novel cleavage site within the VAMP2 cytoplasmic 
portion. Proteolysis on the amino terminal side of K85, R86 
and K87 leaves cytoplasmic portions of no more than ten 
residues or as short as seven residues from the transmembrane 
segment (FIG. 6). It is clear from the chromatogram in FIG. 
5B that VAMP2 incubated as a control in the same experiment 
remains intact. 
A modified version of the cytoplasmic VAMP2 sequence 
was expressed with an altered amino acid sequence compo 
sition replacing the cleavage site. Thus, alanine and serine 
were substituted for lysine and arginine, respectively, so that 
the wild type K85 R86 K87, previously determined to be a 
cleavage site for the FX v metalloprotease activity, was altered 
to A85 S86A87. Based upon results of both PAGE and reverse 
phase chromatography (Cs) these substitutions prevented 
the previously observed cleavage (FIG. 4C), Amino acid 
sequence determinations using the ASA85-87 altered cyto 
plasmic VAMP2 (1-96) following incubation with FX v 
yielded no new amino termini. Based on these data, it is 
concluded that this protein contains only one site for enzy 
matic cleavage, K85 R86K87, and substituting A85 S86 A87 
for this sequence eliminates FX v hydrolysis of cytoplasmic 
VAMP2. 
Example 22 
Fx v also Cleaves VAMP8 and SNAP25 
Bacterially expressed, recombinant human VAMPS (1-74) 
is cleaved upon exposure to Fx v (FIG. 7). The cleavage site 
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is homologous with that determined for VAMP2. The two 
cleavage products are at the N-termini of R67 and K68. This 
cleavage produces 8 (1135.38 Da) and 9 (1291.57 Da) C-ter 
minus residues remaining before the transmembrane seg 
ment. These products are confirmed by mass spectrometry. 
BLASTP aligned sequences are shown in FIG. 6 (top). Simi 
lar results are demonstrated in Western blots of treated guinea 
pig pancreas in vitro (FIG. 1D) and ZG (FIG. 3C). Recombi 
nant WT rat SNAP25 (1-206) is a t-SNARE that is also 
cleaved by Fx v (FIG. 7). However, it does not include trans 
membrane segments since it is attached via near-centrally 
located (palmitoylated) cysteine residues (4 C85, C88, 
C90, and C92). 
Example 23 
Assembled SNARE Complex and FX v 
A cleavage site is identified in the recombinant monomeric 
SNARE component VAMP2 molecules (FIG. 6), which is 
located at the end of the coiled-coil SNARE motif in VAMP2 
(ETSAAKL: (SEQ ID NO:8)) between (L)84 and (K)85); 
cleavage sites also identified after K85 and R86 and also 
before K85, R86, and K87. 
The potential for proteolysis of assembled coiled-coil 
SNAREs was examined next 
The SNARE component proteins, even those without 
attached transmembrane segments can be assembled into 
aligned coiled-coil SNARE structures that share extraordi 
nary characteristics with natural SNARE complexes. These 
characteristics include stability in 2% SDS, 8M urea solu 
tions, and concurrent heating in excess of 80° C. FIG. 8 
demonstrates this unusual stability (Laemmli denaturing gel 
system—14% acrylamide). Assembled (resistant) SNARE 
complex (not boiled) as well as disassembled SNARE com 
plex proteins (boiled for 5 min at 100°C.) both without (lanes 
1 and 2) and with (lanes 3 and 4: 60 minincubation) exposure 
to Fx v are subjected to electrophoresis. FIG. 8 shows that in 
the presence of FX v there is a clear change in staining density 
indicating the occurrence of cleavage by Fx v of both the 
assembled complex (not boiled, lane 3) and the unassembled 
SNARE complex proteins (boiled, lane 4). Individual 
SNARE complex components remain as indicated by the 
presence of residual bands. The visual changes noted are 
representative of numerous PAGE separations of assembled 
SNARE complexes that were treated with FX v. 
Example 24 
Three, unique and distinct divalent (Zinc) binding sites 
have been identified that function as the catalytic centers for 
three of the metalloprotease enzymes of the present invention, 
which target primary SNARE family proteins as facilitators 
for intracellular vesicular traffic in eukaryotic cells. These 
metalloproteases from Scorpion Venom exhibit previously 
unknown primary amino acid sequences with characteristic 
long zinc-binding consensus motif (HExxHxxGXXHD) 
located near the C-terminal. The zinc binding motifs are set 
forth below and in FIG. 10. 
Antarease I HETAHLIGAPHD 
Antarease IIHESVHLLGSPHD 
AZantarease I HESAHLLGSPHD 
The proteolytic function of these enzymes is removed upon 
chelation of the bound zinc with EDTA, and is restored upon 
re-addition. 
The amino acid sequences of three of the isolated proteases 













been determined are set forth in FIG. 10 with the metallopro 
tease consensus sequence shown in the underlined portion of 
each sequence. 
The amino acid sequence of Antarease II and two reverse 
translations of this amino acid sequence are shown in FIG. 11. 
Example 25 
SNARE complex formation is integral to membrane fusion 
in vesicular trafficking and exocytosis in both neuronal and 
non-neuronal cells. Effects of clostridial toxins that cleave 
SNARE proteins in neuronal cells include inhibition of neu 
rotransmitter release (25). In exocrine cells, VAMP2 and 
VAMP8, described in separate Zymogen granule (ZG) popu 
lations, may have different roles but share unique participa 
tion in transport and exocytotic events (42). VAMP2 is 
thought to modulate constitutive secretion while VAMP8 has 
a primary function during regulated Secretion (42, 43). An 
understanding of these functions is fundamental to extending 
knowledge of transport in normal and diseased cells. 
Simultaneous cleavage of multiple SNAREs such as 
VAMP2, VAMPS and VAMPS would presumably have major 
physiological consequences since membrane fusion in exo 
cytosis is SNARE dependentinacinar cells (7). Earlier results 
by the present inventors concerning changes in exocrine pan 
creatic secretory discharge in hyperstimulation may point to 
these specific effects. Current studies are examining whether 
venom-induced VAMP cleavage interferes with pancreatic 
intracellular transport, exocytosis, and response to secretory 
signaling. Cleavage of the V-SNAREs, VAMP2 and VAMP8, 
should result in significant alterations to vesicular transport 
and similarly would impact secretory mechanisms. Tetanus 
neurotoxin cleavage of VAMP2 in pancreatic acini has been 
found to suppress CCK-8 stimulated amylase secretion (44) 
and VAMPS null mice show a major inhibition of CCK 
stimulated regulated pancreatic secretion of amylase while 
maintaining resting secretion. (43). 
EM immunocytochemistry presented herein shows 
decreased colloidal gold labeling of VAMP2 associated with 
mature ZG as a result of apparent venom proteolytic activity 
(FIG. 2). Results define VAMP2 localization to multiple 
points on the ZGM. Also, Au particles were found on 
microvesicle-like structures within the ZG content. Follow 
ing exposure to TSV, few Au particles remain, whether con 
fined to the ZGM or granule content. Enrichment protocols 
with both isolated ZG and ZGM produced similar cleavage 
results. In vitro experiments with ZGM provided limited 
amounts of substrate protein, VAMP2, which has a blocked 
N-terminus (45), as well as interference from similar sized 
intracellular proteins. VAMP2 was expressed in E. coli to 
provide Substrate confirmation in experiments with chro 
matographically purified Scorpion venom metalloprotease 
preparations. 
Amino acid sequencing of cleaved peptides recovered by 
chromatography revealed novel cleavage within the cytoplas 
mic portion of VAMP2. Three consecutive cleavage sites 
were determined to be 7 residues from the transmembrane 
segment—closer than Botulinum A (18 res.), G (13 res.) and 
Tetanus (18 res.) (FIG. 6). Scorpion venom protease activity 
with potential pathogenic mechanisms has not been described 
previously. The amino acid sequence (at the amino terminus) 
of the isolated venom protease is not found in existing amino 
acid sequence databases. This unique Venom protease could 
be penetrating intact tissue, targeting SNARE proteins that 
are cleaved within loop segments outside coiled-coil tet 
rameric SNARE assemblies. 
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Our studies of the effects of scorpion venom and its bioac 
tive protein components presumed that direct effects were 
limited to extracellular or plasma membrane components, 
primarily ion channels (17, 20). Current knowledge of intra 
cellular SNARE cleavage is based upon the metalloprotease 
toxins from Cl. botulinum and Cl. tetani (23, 26). The prin 
cipal clostridial toxins produce VAMP cleavages within the 
region of tetrameric assembly (FIG. 6) (46). Clostridial pro 
tease cleavage is also restricted to single microbial serotypes 
that define single cleavage sites (Id.). The cleavage site pre 
sented herein for the Scorpion Venom metalloprotease is 
within the loop region immediately following the sequence 
directly involved in the coiled-coil tetramer and precedes the 
transmembrane segment that is near the carboxyl terminus 
(FIG. 6). Depending upon the nature of binding and exposure 
of the cleavage site, the Venom metalloprotease may allow for 
cleavage of VAMP2 regardless of its presence in an 
assembled SNARE complex. Findings by other researchers 
(25) reveal that SNARE tetrameric complex assembly pre 
vents proteolysis by clostridial toxins, thus the Venom metal 
loprotease is further distinguished as a having this unique 
proteolytic activity. 
Enzymes in Scorpion venom have not been implicated as 
primary pathology mediators. The relatively abundant scor 
pion Venom enzyme, hyaluronidase, has been considered the 
most important enzyme (47). The role for the hyaluronidase 
activity was thought to be significant only for facilitating 
tissue penetration and distribution of bioactive venom com 
ponents in Vivo, i.e., as in capture of prey or in human enveno 
mation (48). Morphological studies documented that the in 
vitro and in vivo effects of TSV and some component protein 
toxins that produce Secretory discharge and tissue alterations 
are similar to clinical appearances of acute pancreatitis (16. 
49). Secretagogues of non-scorpion venom origin used by 
others can also produce similar effects, but require excessive 
levels of administration in vivo in order to achieve those 
results (50). 
Pathology has been attributed to the presence in scorpion 
venom of ion channel mediator activities (51, 52). These 
neurotoxins are modulators of Voltage-gated Sodium and 
potassium channels, chloride channels and calcium channels. 
There is little correlation between toxin action and physi 
ological effects from Stings except that the autonomic ner 
Vous system is the primary target (52). Until the description 
provided in the present application, no scorpion toxins had 
been associated with intracellular targets. 
Intracellular cleavage of the vesicular SNAREs, VAMP2 
and VAMPS, in exocrine pancreatic acinar cells is reported in 
excised tissue incubated in vitro with Scorpion venom. Immu 
nocytochemistry using EM located major changes in VAMP2 
content in mature ZG following incubation. Studies with 
isolated ZG and ZGM provide reinforcement for these find 
ings. Definitive results were obtained using bacterially 
expressed recombinant, cytoplasmic VAMP2. Amino acid 
sequencing established that the cleavage sites were residues 
Lysine 85, Arginine 86, and Lysine 87. Replacing these 
VAMP2 residues with Alanine 85, Serine 86, and Alanine 87 
resulted in failure of the venom metalloprotease to cleave the 
protein. The cleavage sites are not shared with the sites for the 
only known proteases that target SNARE proteins, the micro 
bial toxins from Cl. botulinum and tetani. 
The foregoing is illustrative of the present invention, and is 
not to be construed as limiting thereof. The invention is 
defined by the following claims, with equivalents of the 
claims to be included therein. 
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<16 Os NUMBER OF SEO ID NOS: 10 
<21 Os SEQ ID NO 1 
&211s LENGTH: 233 
212s. TYPE: PRT 
<213> ORGANISM: Tityus serrulatus 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (177) . . (191) 
<223> 
be any naturally occurring amino acid 
<4 OOs SEQUENCE: 1 






Thir Glu Phe Glu Arg ASn Lieu. Luell 
Met Phe Thir Glin Thir 
35 
Wall Lieu. Luell Luell 
4 O 




Ala Thir Phe 
SO 
Glin Val Ile Gly Pro Lys 
60 
Phe Ile Glu Ser Ala Ile Pro Glin 
70 
Asp Gly 
Wall Wall Asn Met Ala 
85 




Ala Ile Gly Lieu. Asp Asp Met Lieu. 





Ile Wall Glin 
13 O 




Glu Wall Wall 
145 
Ala Glin Ser Asn 
15 O 
Asp Asp Asp Arg 
155 




His Glu. Thir Ala Gly Asp 
Xaa Xala Xala Xala 
185 
Xaa Xala Xala Xala Xala 
18O 
Xaa Xala Xala 
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33 
- Continued 
Phe Ser Lys Cys Thr Llys Lys Cys Val Glu. His Lieu Lleu Ser Lieu Pro 
21 O 215 22O 
Arg Ala Ser Cys Val Lieu Ala Asp Cys 
225 23 O 
<210s, SEQ ID NO 2 
&211s LENGTH: 236 
212. TYPE: PRT 
<213> ORGANISM: Tityus serrulatus 
<4 OOs, SEQUENCE: 2 
Asp Asp Asp Cys Ile Val Val Glu Tyr Tyr Ile Val Thr Asp Ser Ala 
1. 5 1O 15 
Phe Thr Lys Arg Phe Lys Ser Asn Ser Ala Lieu. Thr Asn Tyr Val Thr 
2O 25 3O 
Val Met Phe Thr Gly Val Glin Glu Lieu. Lieu. Asp Thir Lieu. Asn Lieu. Gly 
35 4 O 45 
Ile Gly Val Arg Lieu. Leu Gly Val Thir Thr Phe Thr Glu Lys Thr Glu 
SO 55 6 O 
Pro Ser Phe Ile Lys Asp Asn Lieu. Ile Pro Gly Pro Pro Ala Ala Phe 
65 70 7s 8O 
Asp Pro Asp Val Lieu. Ile Ser Ala Met Ser Lys Tyr Tyr Cys Asn His 
85 90 95 
Glin Thr Gly Lieu Ala Lys Asp Thr Asp Lieu. Ile Phe Lieu. Ile Thr Ala 
1OO 105 11 O 
Arg Gly Met Gly Asp Pro Arg Glu Asp Gly Thr Val Asp Ile ASn Thr 
115 12 O 125 
Ala Gly Ile Ala Asn. Ser Ala Gly Val Cys Llys Pro Cys Phe Llys Ser 
13 O 135 14 O 
Gly Ile Ala Thr Asp Asp Ser Asp Tyr Asn. Glu Arg Val Asp Thir Lieu. 
145 150 155 160 
Ala His Glu Ser Val His Lieu. Lieu. Gly Ser Pro His Asp Gly Glu Gly 
1.65 17O 17s 
Pro Asn Lieu Val Ser Lieu. Gly Ser Pro Gly Ala Ala Asn. Cys Pro Ala 
18O 185 19 O 
Lys Ala Gly Tyr Ile Met Gly Asn Arg Asn Asp Llys Val Asn Llys Tyr 
195 2OO 2O5 
Llys Phe Ser Asn. Cys Thr Llys Lys Cys Val Glu Tyr Lieu. Lieu. Ser Lys 
21 O 215 22O 
Pro Thr Ala Ser Cys Ile Phe Glin Gln Cys Ser Asp 
225 23 O 235 
<210s, SEQ ID NO 3 
&211s LENGTH: 235 
212. TYPE: PRT 
<213> ORGANISM: Centruroides sculpturatus 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (179) . . (192) 
<223> OTHER INFORMATION: Xaa is optionally present or absent and can 
be any naturally occurring amino acid 
<4 OOs, SEQUENCE: 3 
Lys Asp Glin Cys Ile Val Val Glu. Cys Lieu Val Val Thr Glu Ser Ala 
1. 5 1O 15 
Phe Thr Lys Arg Phe Glu Thir Thr Lys Ala Lieu. Thr Glu Tyr Val Thr 









































































<210s, SEQ ID NO 4 
&211s LENGTH: 
212. TYPE : 
<213> ORGANISM: Centruroides sculpturatus 
PRT 








































































































































Ser Gly Lys Cys Ile Ile Val Asp Cys Lieu Val Lieu. Thr Glu Asn Ala 
1. 
Phe Thr Lys Arg 
5 
<210s, SEQ ID NO 5 
&211s LENGTH: 
212. TYPE : 
&213s ORGANISM: 
PRT 
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- Continued 
Lys Gly Lieu Ala Lys Asp Ala Asp Ile Ile Met Lieu. Ile Ser Asn Arg 
1OO 105 11 O 
Llys Lieu. Gly Glu Lieu. Glin Asp Asp Gly Thr Val Ala Tyr Asn. Thir Ala 
115 12 O 125 
Gly Ile Ser Lieu. Gly Ser Gly Val Cys Lys Glin Cys Ser Llys Val Gly 
13 O 135 14 O 
Val Ala Glin Asp Asp Ser Asp Tyr Asn. Glu Arg Val Asp Thr Val Ala 
145 150 155 160 
His Glu Thir Ala His Lieu. Ile Gly Ala Pro His Asp Glu Glu Gly Pro 
1.65 17O 17s 
<210s, SEQ ID NO 6 
&211s LENGTH: 42 
212. TYPE: PRT 
<213> ORGANISM: Tityus serrulatus 
<4 OOs, SEQUENCE: 6 
Ser Asp Gly Tyr Ile Met Gly Ser Gly Asn. Asn Llys Val Asn Llys Phe 
1. 5 1O 15 
Llys Phe Ser Lys Cys Thr Llys Lys Cys Val Glu. His Lieu. Lieu. Ser Lieu. 
2O 25 3O 
Pro Arg Ala Ser Cys Val Lieu Ala Asp Cys 
35 4 O 
<210s, SEQ ID NO 7 
&211s LENGTH: 178 
212. TYPE: PRT 
<213> ORGANISM: Centruroides sculpturatus 
<4 OO > SEQUENCE: 7 
Lys Asp Glin Cys Ile Val Val Glu. Cys Lieu Val Val Thr Glu Ser Ala 
1. 5 1O 15 
Phe Thr Lys Arg Phe Glu Thir Thr Lys Ala Lieu. Thr Glu Tyr Val Thr 
2O 25 3O 
Val Met Tyr Thr Gly Val Glin Asn Lieu. Ile Asp Thr Lieu Gln Leu Gly 
35 4 O 45 
Ile Llys Phe Arg Lieu. Lieu. Gly Ile Asp Pro Phe Thr Lys Glu Thr Glu 
SO 55 6 O 
Pro Pro Tyr Ile Glu Glu Ser Ala Asn Pro Val Asn Pro Llys Tyr Lieu. 
65 70 7s 8O 
Asn Pro Lieu. Asp Lieu. Ile Asp Arg Met Gly Lys Tyr Tyr Cys Asn His 
85 90 95 
Ala Thr Gly Lieu Ala Lys Asp Ala Asp Met Ile Met Lieu. Lieu Val Thr 
1OO 105 11 O 
Arg Asn Lieu. Gly Glu Lieu Lys Asp Asp Gly Thr Val Llys Phe Arg Val 
115 12 O 125 
Val Gly Lieu Ala Tyr Lys Gly Ala Val Cys Lys Glin Cys Tyr Llys Val 
13 O 135 14 O 
Gly Val Cys Lys Asp Asp Ser Tyr Tyr Asn. Glu Arg Val Asp Thr Val 
145 150 155 160 
Ala His Glu Ser Ala His Lieu. Lieu. Gly Ser Pro His Asp Gly Glu Pro 
1.65 17O 17s 
Gly Ala 
<210s, SEQ ID NO 8 
&211s LENGTH: 43 









(54) . . (54) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (60) . . (60) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (69) . . (69) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (75) . . (75) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (78) . . (78) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (81) . . (81) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (84) . . (84) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (93 ) . . (93) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (96) ... (96) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (99).. (99) 
FORMATION: n is a, c, g, t or u. 
misc feature 
; (108) ... (108) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (111) . . (111) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (114) . . (114) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (123) . . (123) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (126) . . (126) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (132) . . (132) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (135) . . (135) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (141) . . (141) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (144) . . (144) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (150) ... (150) 













KEY: misc feature 
LOCATION: (153) . . (153) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (156) ... (156) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (159) . . (159) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (162) ... (162) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (165) . . (165) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (168) ... (168) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (171) . . (171) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (174) . . (174) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (180) ... (180) 
INFORMATION: n is a, c, g, t or u. 
RE; 
KEY: misc feature 
ION: (189) . . (189) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (195) . . (195) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (198) ... (198) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (216) ... (216) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (222) ... (222) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (225) ... (225) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (228) ... (228) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (231) ... (231) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (234) ... (234.) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (237) ... (237) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 















































































) ... (366) 
ON: n is 
feature 
) ... (369) 
ON: n is 
feature 
) ... (372) 
ON: n is 
feature 
) ... (384) 
ON: n is 
feature 
) ... (387) 
ON: n is 
feature 
) ... (390) 
ON: n is 
feature 
) ... (396) 
ON: n is 
feature 
) . . (402) 
ON: n is 
feature 
) ... (405) 
ON: n is 
feature 
) . . (408) 
ON: n is 
feature 
) . . (411) 
ON: n is 
feature 
) . . (420) 
ON: n is 
feature 
) . . (432) 
ON: n is 
feature 
) ... (435) 
ON: n is 
feature 
) . . (441) 
ON: n is 
feature 
) . . (444) 
ON: n is 
feature 
) ... (453) 
ON: n is 
feature 
) ... (468) 
ON: n is 
feature 
) ... (471) 
ON: n is 
feature 
) ... (4.77) 
































(480) ... (480) 
FORMATION: n is a, c, g, t or u. 
misc feature 
; (483) ... (483) 
FORMATION: n is a, c, g, t or u. 
misc feature 
; (492) ... (492) 
FORMATION: n is a, c, g, t or u. 
misc feature 
; (495) ... (495) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (501) . . (501) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (504) . . (504) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (507) . . (507) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (510) ... (510) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (513) . . (513) 
FORMATION: n is a, c, g, t or u. 
misc feature 
; (522) ... (522) 
FORMATION: n is a, c, g, t or u. 
misc feature 
; (528) ... (528) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (531) . . (531) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (537) . . (537) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (540) ... (540) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (543) . . (543) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (546) ... (546) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (549) . . (549) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (552) ... (552) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (555) . . (555) 
FORMATION: n is a, c, g, t or u. 
misc feature 
: (558) ... (558) 













KEY: misc feature 
LOCATION: (561) . . (561) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (564) . . (564) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (573 ) . . (573) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (576) ... (576.) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (582) ... (582) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (585) . . (585) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (597) . . (597) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (603) . . (603) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (615) . . (615) 
INFORMATION: n is a, c, g, t or u. 
RE; 
KEY: misc feature 
ION: (633) . . (633) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (642) ... (642) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (654) . . (654) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (663) . . (663) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (666) . . (666) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ION: (669) . . (669) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (675) . . (675) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (678) ... (678) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (681) . . (681) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (684) . . (684) 
INFORMATION: n is a, c, g, t or u. 
RE: 
KEY: misc feature 
ON: (705) . . (7 O5) 
US 9,149,666 B2 
53 54 
- Continued 
<223> OTHER INFORMATION: n is a, c, g, t or u. 
<4 OOs, SEQUENCE: 10 
gaygaygayt gyathgtngt ngartaytay athgtnacing aywsngcntt yacna armgn 6 O 
tityaarwsna aywsngcnyt nacnaaytay gtnacingtna tottyacingg ngtncargar 12 O 
ytnytingaya cnytnaayyt nggnathggn gtnmgnytny tinggingtmac nacinttyacin 18O 
garaaracng arc cnwSntt yathaargay aayytnathc cng gnc cinc c ngc.ngcntity 24 O 
gay.cc.ngayg trhytnathws ngcnatgWSn aartaytayt gyaaycayca racinggnytn 3OO 
gCnaargaya Cingayytnat httyytnath acngcnmgng gnatggginga y CCnmgngar 360 
gayggnacing trhayathaa yacing Cnggn athgcnaayW SingCnggingt ntgyaarc.cn 42O 
tgyttyaarw sing gnathgc nacingaygay WSngaytaya aygarmgngt ngayacnytn 48O 
gCncaygarW Sngtncayyt nytinggnWSn CCncaygayg gngarggnc c naayytingtn 54 O 
WSnytinggnW Snc CinggingC ngc.naaytgy CCngcnaarg Cinggntayat hatgggnaay 6OO 
mgnaaygaya argtnaayaa rtayaartty WSnaaytgya cnaaraartg yogtingartay 660 
ytnytnwsna arc Cnacingc nWSntgyath tty carcart gyWSngay 7 OS 
That which is claimed is: 
1. An isolated polypeptide comprising an amino acid 
sequence selected from the group consisting of (1) SEQ ID 
NO:1, (2) SEQ ID NO:2, (3) SEQ ID NO:3, (4) SEQ ID 
NO:4, (5) a combination of SEQID NO:5 and SEQID NO:6, 
and (6) a combination of SEQID NO:7 and SEQID NO:8, or 
a biologically active fragment thereof, wherein the isolated 
polypeptide is a 6-His fusion polypeptide having the activity 
of proteolytic cleavage of SNAP25, VAMP2 and VAMP8. 
2. An isolated nucleic acid encoding a polypeptide com 
prising an amino acid sequence selected from the group con 
sisting of (1) SEQID NO:1, (2) SEQID NO:2, (3) SEQ ID 
NO:3, (4) SEQID NO:4, (5) a combination of SEQID NO:5 
and SEQ ID NO:6, and (6) a combination of SEQID NO:7 
and SEQ ID NO:8, wherein the encoded polypeptide is a 
6-His fusion polypeptide. 
3. An isolated nucleic acid encoding a nucleotide sequence 
selected from the group consisting of: 
(a) a nucleotide sequence encoding a polypeptide compris 
ing an amino acid sequence selected from the group 
consisting of (1) SEQ ID NO:1, (2) SEQ ID NO:2, (3) 
SEQ ID NO:3, (4) SEQID NO:4, (5) a combination of 
SEQID NO:5 and SEQID NO:6, and (6) a combination 
of SEQ ID NO:7 and SEQ ID NO:8, wherein the 
encoded polypeptide is a 6-His fusion polypeptide; 
(b) a nucleotide sequence having at least 85% sequence 
identity to a nucleotide sequence encoding a polypeptide 
comprising an amino acid sequence selected from the 
group consisting of (1) SEQID NO:2, (2) SEQID NO:4, 
(3) a combination of SEQID NO:5 and SEQID NO:6, 
and (4) a combination of SEQ ID NO:7 and SEQ ID 
NO:8, wherein the encoded polypeptide is a 6-His fusion 
polypeptide having the activity of proteolytic cleavage 
of SNAP25, VAMP2 and VAMP8; and 
(c) a nucleotide sequence that differs from the nucleotide 
sequences of (a) or (b) above due to the degeneracy of 
the genetic code. 
4. An isolated nucleic acid encoding a nucleotide sequence 









(a) the nucleotide sequence of SEQID NO:9; 
(b) a nucleotide sequence having at least 85% sequence 
identity to (a) above and wherein the encoded polypep 
tide has the activity of proteolytic cleavage of SNAP25, 
VAMP2 and VAMP8; and 
(c) a nucleotide sequence that differs from the nucleotide 
sequences of (a) or (b) above due to the degeneracy of 
the genetic code. 
5. A composition comprising the isolated polypeptide of 
claim 1 in a pharmaceutically acceptable carrier. 
6. A method of treating muscle spasms in a subject by 
administering to said Subject an effective amount of the com 
position of claim 5. 
7. A method of treating a cosmetic condition in a Subject, 
comprising administering to the Subject an effective amount 
of the composition of claim 5, wherein the cosmetic condition 
is selected from the group consisting of frown wrinkles, fore 
head wrinkles, crow's feet, nose crease wrinkles, and any 
combination thereof. 
8. A method of treating a disorder in a Subject, comprising 
administering to the Subject an effective amount of the com 
position of claim 5, wherein the disorder is selected from the 
group consisting of Strabismus, blepharospasm, headaches, 
cervical dystonia, severe primary axillary hyperhidrosis, pro 
static symptoms, asthma, post stroke spasticity diabetes, 
obstructive pulmonary disease, achalasia, and any combina 
tion thereof. 
9. A vector comprising an isolated nucleic acid sequence of 
claim 2. 
10. A vector comprising an isolated nucleic acid sequence 
of claim 3. 
11. A vector comprising an isolated nucleic acid sequence 
of claim 4. 
12. The composition of claim 5, wherein the pharmaceuti 
cally acceptable carrier comprises sterile pyrogen-free water 
and/or sterile pyrogen-free physiological Saline solution. 
13. A composition comprising the isolated polypeptide of 
claim 1 comprising a cosmetically acceptable carrier. 
14. The composition of claim 13, wherein the cosmetically 
acceptable carrier is in the form of a spray, an emulsion, a 
mousse, a liquid, a cream, an oil, a lotion, an ointment, a gel 
or a solid. 
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15. A method of treating a cosmetic condition in a Subject, 
comprising administering to the Subject an effective amount 
of the composition of claim 13, wherein the cosmetic condi 
tion is selected from the group consisting of frown wrinkles, 
forehead wrinkles, crow's feet, nose crease wrinkles, and any 5 
combination thereof. 
16. A method of treating a cosmetic condition in a Subject, 
comprising administering to the Subject an effective amount 
of the composition of claim 14, wherein the cosmetic condi 
tion is selected from the group consisting of frown wrinkles, 10 
forehead wrinkles, crow's feet, nose crease wrinkles, and any 
combination thereof. 
17. A method of expressing the nucleotide sequence of 
SEQID NO:9 in a host cell, comprising: 
introducing into a host cell the nucleotide sequence of SEQ 15 
ID NO:9, thereby expressing the nucleotide sequence of 
SEQ ID NO:9 in a host cell. 
18. A method of expressing an isolated nucleic acid 
sequence of claim 2 in a host cell, comprising: 
introducing into a host cell the isolated nucleic acid 20 
sequence of claim 2, thereby expressing the isolated 
nucleic acid sequence of claim 2 in a host cell. 
19. A method of expressing an isolated nucleic acid 
sequence of claim 3 in a host cell, comprising: 
introducing into a host cell the isolated nucleic acid 25 
sequence of claim 3, thereby expressing the isolated 
nucleic acid sequence of claim 3 in a host cell. 
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